Protocol (a) : I8F-MC-GPHU 
 
The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non- diabetic  
Subjects and in Overweight/Obese Subjects with Type 2 Diabetes Mellitus 
 [STUDY_ID_REMOVED] 
Approval Date: 23-Jul-2020 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e 1
L Y 3 2 9 8 1 7 6 Pr ot o c ol I 8 F -M C -G P H U ( a) 
T h e I m p a ct of Tir z e p ati d e o n G a stri c E m pt y i n g ( G E) i n 
O v er w ei g ht/ O b e s e N o n -di a b eti c S u bj e ct s a n d i n 
O v er w ei g ht/ O b e s e S u bj e ct s wit h T y p e 2 Di a b et e s M ellit u s 
C o nfi d e nti al I nf or m ati o n 
T h e i nf or m ati o n c o nt ai n e d i n t hi s pr ot o c ol i s c o nfi d e nti al a n d i s i nt e n d e d f or t h e u s e of 
cli ni c al i n v e sti g at or s.  It i s t h e pr o p ert y of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s a n d 
s h o ul d n ot b e c o pi e d b y or di stri b ut e d t o p er s o n s n o t i n v ol v e d i n t h e cli ni c al i n v e sti g ati o n of 
tir z e p ati d e ( L Y 3 2 9 8 1 7 6) , u nl e s s s u c h p er s o n s ar e b o u n d b y a c o nfi d e nti alit y a gr e e m e nt 
wit h Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
N ot e t o R e g ul at or y A ut h oriti e s:   T hi s d o c u m e nt m a y c o nt ai n pr ot e ct e d p er s o n al d at a 
a n d/ or c o m m er ci all y c o nfi d e nti al i nf or m ati o n e x e m pt fr o m p u bli c di s cl o s ur e.  Eli Lill y a n d 
C o m p a n y r e q u e st s c o n s ult ati o n r e g ar di n g r el e a s e/r e d a cti o n pri or t o a n y p u bli c r el e a s e.  I n 
t h e U nit e d St at e s, t hi s d o c u m e nt i s s u bj e ct t o Fr e e d o m of I nf or m a ti o n A ct ( F OI A) 
E x e m pti o n 4 a n d m a y n ot b e r e pr o d u c e d or ot h er wi s e di s s e mi n at e d wit h o ut t h e writt e n 
a p pr o v al of Eli Lill y a n d C o m p a n y or it s s u b si di ari e s. 
Tir z e p ati d e ( L Y 3 2 9 8 1 7 6 )
Eli Lill y a n d C o m p a n y 
I n di a n a p oli s, I n di a n a U S A 4 6 2 8 5 
Cli ni c al P h ar m a c ol o g y Pr ot o c ol El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y o n 3 0 A pr 
2 0 2 0. 
A m e n d m e nt ( a) El e ctr o ni c all y Si g n e d a n d A p pr o v e d b y Lill y 
o n a p pr o v al d at e pr o vi d e d b el o w 
A p pr o v al D at e: 2 3- J ul- 2 0 2 0 G M T 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_116985] of Tirzepatide on Gastric Empty ing (GE) in 
Overweight/Obese Non-diabetic Subjects and in 
Overweight/Obese Subjects with Ty pe 2 Diabetes Mellitus
Section Page
Protocol  I8F-MC-GPHU (a)The Impact of Tirzepatide on Gastric 
Emptying (GE) in Overweight/Obese Non -diabet ic Subj ects and in 
Overweight/Obese Subjects with Ty pe [ADDRESS_116986] ivities....................................................................................................... 11
3. Introduction ...................................................................................................................... 15
3.1. Study  Rati onale............................................................................................................ 15
3.2. Background .................................................................................................................. 15
3.3. Benefit/Risk Assessment .............................................................................................. [ADDRESS_116987] ives and Endpo ints.................................................................................................. 17
5. Study  Design ..................................................................................................................... 18
5.1. Overall Design ............................................................................................................. 18
5.2. Number of Parti cipants .................................................................................................19
5.3. End of Study  Definit ion............................................................................................... 19
5.4. Scientific Rationale for Study  Design ........................................................................... 19
5.5. Justification for Dose ................................................................................................... 19
6. Study Populat ion............................................................................................................... 20
6.1. Inclusio n Cri teria.......................................................................................................... 20
6.2. Exclusio n Cri teria........................................................................................................ 23
6.3. Lifes tyle and/or Dietary  Requirements ......................................................................... 26
6.3.1. Meals and Dietary  Restri ctions............................................................................. 27
6.3.2. Caffeine, Alcoho l, and Tobacco ........................................................................... 27
6.3.3. Activity................................................................................................................ 27
6.4. Screen Failures ............................................................................................................. 27
7. Treatment .......................................................................................................................... 28
7.1. Treatment Admin istered ............................................................................................... 28
7.1.1. Packaging and Labeling ....................................................................................... 29
7.2. Method of Treatment Assignment ................................................................................ 29
7.2.1. Selection and Timing o f Doses ............................................................................. 29
7.3. Blinding ....................................................................................................................... 29
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e 3
L Y 3 2 9 8 1 7 6 7. 4. D ose M o dificat i o n........................................................................................................ 2 9 
7. 5. Pre parati o n/ Ha n dli n g/ St ora ge/ Acc o u nta bilit y............................................................... [ADDRESS_116988] as ma Gl uc ose ( S M P G) ........................................................ 4 1 C CI 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 4
LY32981769.4.9. Suicidal  Ideat ion Assessment ............................................................................... 42
9.4.10. Safety Moni toring ................................................................................................ 42
[IP_ADDRESS]. Hepati c Safet y................................................................................................ [ADDRESS_116989] ics.......................................................................... 48
10.3. Statistical Analyses ...................................................................................................... 48
10.3.1. Safety Analyses .................................................................................................... 48
[IP_ADDRESS]. Clinical Evaluation of Safet y.......................................................................... 48
[IP_ADDRESS]. Statistical Evaluat ion of Safet y....................................................................... 49
10.3.2. Pharmacokinet ic Analyses .................................................................................... 49
[IP_ADDRESS]. Pharmacokinet ic Parameter Estimat ion........................................................... 49
[IP_ADDRESS]. Pharmacokinet ic Statistical Inference ............................................................. 49
10.3.3. Pharmacodynamic Analyses ................................................................................. 49
[IP_ADDRESS]. Pharmacodynamic Parameter Estimation ........................................................ 49
[IP_ADDRESS]. Pharmacodynamic Statistical Inference ........................................................... 49
10.3.4. Evaluat ion of Immunogenicit y............................................................................. 50
10.3.5. Interim Analyses .................................................................................................. 50
11. References ........................................................................................................................ 51
12. Appendices ....................................................................................................................... 53
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_116990] ives and Endpo ints....................................................................... 17
Table GPHU.2. Treatments Administered ........................................................................ 28
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_116991] of Figures
Figure Page
Figure GPHU.1. Illustrati on of  study  design for Protocol I8F -MC-GPHU. ........................ 18
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_116992] of Appendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions................................................................ 54
Appendix 2. Clinical Laboratory  Tests ........................................................................ 58
Appendix 3. Study  Governance, Regulatory  and Ethi cal Considerati ons..................... 59
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergen t Abnorm ality............ 62
Appendix 5. Blood Sam pling Summary ...................................................................... 64
Appendix 6. Pancreat ic Monitoring ............................................................................ 65
Appendix 7. Protocol  Amendment I8F -MC-GPHU (a) Summary 
The Im pact of  Tirzepat ide on Gastric Emptying (GE) in 
Overweight/Obese Non -diabetic Subjects and in 
Overweight/Obese Subjects with Ty pe 2 Di abetes Mellitus .................... 67
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 8
LY32981761.Protocol Synopsis
Title of Study:
The Impact of Tirzepatide on Gastric Emptying (GE) in Overweight/Obese Non -diabetic Subjects and in 
Overweight/Obese Subjects with Type 2 Diabetes Mellitus
Rationale: 
Tirzepatide (LY3298176) is a dual glucose -dependent insulinotropic peptide (GIP) and glucagon -like peptide 1 
(GLP -1) receptor agonist being developed as an adjunct to diet and exercise for chronic weight management in adult 
patients with or without type 2 diabetes mellitus (T2DM) who have an initial body mass index (BMI) of 30 kg/m 2or 
greater (obese) or 27 kg/m 2or greater (overweight).   The impact of tirzepatide on gastric emptying (GE) has been 
assessed in healthy subjects and in patients with T2DM using acetaminophen pharmacokinetics (PK) as a surrogate 
(Study I8F -MC -GPGA).  However, data on the GE effects of tirzepatide in overweight/obese non -diabetic subjects 
are presently lacking.
Study I8F -MC -GPHU (GPHU) will assess the effect of multiple doses of t irzepatide (5 to 15 mg/0.5 mL) on the PK 
of acetaminophen to determine the impact on gastric emptying (GE) , and the pharmacodynamics (PD), safety and 
tolerability of tirzepatide in overweight/obese non -diabetic subjects and overweight/obese T2DM subjects w hen 
administered using a prefilled syringe (PFS).
Objectives /Endpoints:
Objectives Endpoints
Primary
To assess the effect of tirzepatide on the PK profile of 
acetaminophen, a marker for GEAcetaminophen area under the concentration versus 
time curve from time zero to time t, where t is the last 
time point with a measurable concentration 
(AUC 0-tlast), time of maximum observed drug 
concentration (tmax), maximum observed drug 
concentration (Cmax)
Secondary
To evaluate tirzepatide PK and PD effects following
multiple doses of SC tirzepatide in overweight/obese 
non-diabetic subjects and overweight/obese T2DM 
subjects
To evaluate tirzepatide safety and tolerability following 
multiple doses of SC tirzepatide in overweight/obese 
non-diabetic subjects and overwei ght/obese T2DM 
subjectsGlycemic control (plasma glucose, HbA1c), and 
tirzepatide area under the concentration versus time 
curve from time zero to infinity (AUC 0-∞),AUC 0-tlast, 
tmax, Cmax
Adverse events and hypoglycemic events
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e [ADDRESS_116993] u d y Desi g n :
T his is a n o pe n -la bel, fi xe d se q ue nce st u d y i n o ver wei g ht/ o bese n o n -dia betic s u bjects a n d o ver wei g ht/ o bese T [ADDRESS_116994] u d y wit hi n 2 8 da ys pri or t o Da y 1.  
S u bjects will be a d mitte d t o t he C R U o n Da y -3 a n d will esta blis h baseli ne meas ure me nts d uri n g t he Baseli ne 
Peri o d fr o m Da ys -3 t o -1. 
S u bjects will recei ve s u bc uta ne o us tirze pati de 5 m g o n Da ys 1 a n d 8; 1 0 m g o n Da ys 1 5, 2 2, a n d 2 9; a n d [ADDRESS_116995] o n 
Da ys 8 ( ± 1 da y ), 1 5 ( ± 1 da y), 2 2 ( ± 1 da y), 2 9 ( ± 1 da y), a n d 4 3 ( ± 2 da ys). 
A fi nal f oll o w -u p visit will occ ur o n Da y 6 4 ± 1 da y (i . e ., 2 8 da ys ± 1 da y after t he fi nal tirze p ati de d ose). 
Safet y will be assesse d b y vital si g ns, E C Gs, , safet y la b orat or y tests, a n d t he 
rec or di n g of A Es .  P h ar mac o ki netic bl o o d sa m ples f or aceta mi n o p he n a n d tirze pati de will be c ollecte d. 
Tre at me nt Ar ms a n d Pl a n ne d Dur ati o n f or a n I n di vi d u al S u bject :  
T he st u d y  d urati o n f or i n di vi d ual s u bjects, i ncl usi ve of scree ni n g is e x pecte d t o be a p pr o xi matel y 1 3 wee ks, di vi de d 
as f oll o ws: 
Scree ni n g:  u p t o 2 8 da ys pri or t o Da y 1 
Treat me nt Peri o d:  Da y 1 t o Da y 4 3 ( ± 2 da ys) 
F oll o w -u p:  Da y  6 4 ( ± 1 da y) will be c o nsi dere d as t he fi nal f oll o w -u p visit 
N u m ber of S u bjects: 
A p pr o xi matel y [ADDRESS_116996] atistic al A n al ysis: 
T he pri mar y para meters f or a nal ysis will be C m a x , A U C 0- ∞ ,A U C 0-t last , a n d t ma x .
P har mac o ki netic para meters will be e val uate d t o esti mate t he i m pact of tirze pati de o n G E a n d o n t he P K of 
aceta mi n o p he n.  L o g -tra nsf or me d C m a x a n d A U C will be e val uate d i n a li near mi xe d -effects m o del, wit h da y 
(- 1, 2, 3 7) as a fi xe d effect a n d s u bject as a ra n d o m effect.  T he differe nces i n C m a x a n d A U C bet wee n 
aceta mi n o p he n + tirze pati de ( Test; Da ys 2 a n d 3 7) a n d aceta mi n o p he n al o ne ( Refere nce; Da y -1) will be 
bac k -tra nsf or me d t o prese nt t he rati os of ge o metric least s q uares mea ns a n d t he c orres p o n di n g 9 0 % CI.  Ot her 
para meters ma y be a nal yze d i n t his wa y as nee de d. 
T he t ma x will be a nal yze d usi n g a Wilc o x o n si g ne d ra n k test.  Esti mates of t he me dia n differe nce base d o n t he 
obser ve d me dia ns a n d 9 0 % CIs fr o m t he Wilc o x o n test will be calc ulate d. C CI 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e 1 0 
L Y 3 2 9 8 1 7 6 Pla n ne d P K para meters will als o be s u m marize d wit h descri pti ve statistics. 
Phar mac o d y na mic para meters t hat will be assesse d i ncl u de b o d y wei g ht, a p petite Vis ual A nal o g Scale ( V A S )sc ores 
a n d H b A 1c.  T he para meters will be liste d a n d s u m marize d usi n g sta n dar d descri pti ve statistics.  A d diti o nal a nal ysis 
will be perf or me d if warra nt e d u p o n re vie w of t he data.  
Safet y para meters t hat will be assesse d i ncl u de safet y la b orat or y para meters, vital si g ns,  
 T E A Es (i ncl u di n g T E A Es of s pecial i nterest), a n d S A Es.  T he para meters will be liste d a n d s u m marize d 
usi n g sta n dar d descri pti ve statistics.  A d diti o nal a nal ysis will be perf or me d if warra nte d u p o n re vie w of t he data.  
All A Es relate d t o st u d y or pr ot oc ol pr oce d ure will be liste d, a n d if t he fre q ue nc y of e ve nts all o ws, will be als o 
s u m marize d usi n g descri p ti ve met h o d ol o g y.   H y p o gl yce mic e ve nts will be s u m marize d a n d liste d. 
P h y sical e xa mi nati o ns a n d E C Gs will be perf or me d f or safet y m o nit ori n g p ur p oses a n d will n ot be prese nte d.  
If warra nte d, a d diti o nal a nal yses will be perf or me d u p o n re vie w of t he data. C CI 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 11
LY32981762.Schedule of A ctivities
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e [ADDRESS_116997] u d y Sc he d ule Pr ot oc ol I 8 F -M C -G P H U Scree ni n g a n d B aseli ne 
Scree ni n g B aseli ne 
C o m me nts 
Pr oce d ure D- 2 8 t o - 4  D- 3 D- 2  D- 1 
I n f or me d C o nse nt X
A d missi o n t o C R U X E nr oll me nt will occ ur o n Da y -2 after cleari n g me dical assess me nt. 
O ut patie nt visits t o C R U X
Re vie w a n d c o nfir m i ncl usi o n / 
e xcl usi o n criteria X
Me dical Hist or y X
P h ysical E xa m / Me dical Assess me nt X X F ull p h ysical e xa mi nati o n at scree ni n g. T hereafter, assess me nts perf or me d t o i ncl u de 
me dical re vie w a n d tar gete d e xa mi nati o n, as a p pr o priate. 
Hei g ht ,Wei g ht , a n d B MI X Refer t o Secti o n 9. 4. [ADDRESS_116998] be assesse d t o c o nf or m t o I ncl usi o n Criteri o n [ 2]. 
Waist Circ u mfere nce X X Refer t o Secti o n 9. 4. [ADDRESS_116999] 
stri ps, a n d diaries /c o n d uct S M P G a n d 
h y p o gl yce mia trai ni n g A n y ti me fr o m Da y -[ADDRESS_117000] meals. Meals = brea kfast, l u nc h a n d di n ner. 
C- S S R S ( baseli ne / scree ni n g f or m) + 
S H S F + S H F F XT he S H F F is o nl y re q uire d o nl y if tri g gere d b y t he S H S F, per i nstr ucti o ns i n t he f or m. 
P H Q - [ADDRESS_117001] be s u pi [INVESTIGATOR_050] f or a p pr o xi matel y 5 t o 1 0 mi n utes 
bef ore E C G c ollecti o n a n d re mai n s u pi [INVESTIGATOR_050] b ut a wa ke d uri n g E C G c ollecti o n. 
S u pi [INVESTIGATOR_105395] g ns X X A d diti o n al ti me p oi nts ma y be a d de d at t he i n vesti gat or ’s cli nical j u d g me nt .
Cli nical La b orat or y Tests X X See A p pe n di x [ADDRESS_117002] 
be rec or de d.   Aceta mi n o p he n P K sa m pli n g ti mes are relati ve t o aceta mi n o p he n d osi n g 
( 0 h o urs). Aceta mi n o p he n 1 g d ose 0
Aceta mi n o p he n P K sa m pli n g ( h o urs) - 0. [ADDRESS_117003] u g Scree n X
A Es/ C o nc o mita nt Me dicati o ns X  X  X  X C CI 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e [ADDRESS_117004] u d y Sc he d ule Pr ot oc ol I 8 F -M C -G P H U Tre at me nt a n d F oll o w -u p 
Tre at me nt a n d F oll o w U p C o m me nts 
Pr oce d ure D 1  D 2  D 3  D 4  D 8 
± 1 D 1 5 
± 1 D 2 2 
± 1 D 2 9 
± 1 D 3 5 D 3 6  D 3 7  D 3 8  D 4 3 
± 2 F U/ 
E D a
A d missi o n t o C R U X
Disc har ge fr o m 
C R U X D 3 9 C R U sta y ma y be e xte n de d a t t he 
i n vesti gat or’s discreti o n. 
O ut patie nt Visit X  X  X  X X  X 
Pre g na nc y test X
Me dical 
Assess me nt P P P P P X
Wei g ht a n d B MI P P P P P X  X Refer t o Secti o n 9. 4. [ADDRESS_117005] 
circ u mfere nce s h o ul d be meas ure d. 
Te m perat ure P P P P P X
Safet y 1 2 -lea d 
E C G ( h o urs) P, 1 2 X  X  X P P P P P, 1 2 X  X  X  X Refer t o scree ni n g a n d baseli ne c o m me nts. 
S u pi [INVESTIGATOR_105395] g ns 
( h o urs) P, 1 2 X  X  X P P P P P, 1 2 X  X  X  X A d diti o n al ti me p oi nts ma y be a d de d at 
t he i n vesti gat or ’s cli nical j u d g me nt .
Cli nical La b orat or y 
Tests P P X  X Refer t o scree ni n g a n d baseli ne c o m me nts 
Plas ma gl uc ose X P P P P P X  X  X 
6-p oi nt plas ma 
gl uc ose pr ofile X X Refer t o scree ni n g a n d baseli ne c o m me nts. 
S M P G Perf or me d pre -brea kfast, pre -l u nc h a n d pre -di n ner a n d bef ore be dti me f or at least [ADDRESS_117006] 2 da ys per wee k (as 6 -p oi nt plas ma gl uc ose pr ofile will be perf or me d 
d uri n g i n patie nt visits). A p plica ble t o T [ADDRESS_117007] 
diaries. 
A Es/ C o n me ds X  X  X  X  X  X  X  X  X  X  X  X  X  X 
A p petite A nal ysis 
b y Vis ual A nal o g 
Scale ( V A S) P  X  X P  X  X  X Refer t o Secti o n 9. 9 . T o be perf or me d 
pri or t o d osi n g a n d/ or brea kfast. 
Meal -0. 5 -0. 5 Refer t o scree ni n g a n d baseli ne c o m me nts. 
Aceta mi n o p he n 1 g 
d ose 0 0C CI 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e 1 4 
L Y 3 2 9 8 1 7 6 Tre at me nt a n d F oll o w U p C o m me nts 
Pr oce d ure D 1  D 2  D 3  D 4  D 8 
± 1 D 1 5 
± 1 D 2 2 
± 1 D 2 9 
± 1 D 3 5 D 3 6  D 3 7  D 3 8  D 4 3 
± 2 F U/ 
E D a
Aceta mi n o p he n 
P K sa m pli n g 
( h o urs) [ADDRESS_117008] be rec or de d.   
Aceta mi n o p he n P K sa m pli n g ti mes are 
relati ve t o aceta mi n o p he n d osi n g 
( 0 h o urs).  [ADDRESS_117009] be ta ke n pri or t o tirze pati de 
d osi n g. 
Tirze pati de d osi n g X X  X  X  X  X Da y s1 a n d 8 = 5 m g; D a y s 1 5, 2 2, a n d 
2 9 = 1 0 m g; Da y 3 6 = 1 5 m g. All 
tirze pati de d oses will be a d mi nistere d 
s u bc uta ne o usl y as detaile d i n Secti o n 7. 1 .
Tirze pati de P K 
Sa m pli n g ( h o urs )P, 8, 
[ADDRESS_117010] be rec or de d. 
P K sa m pli n g ti mes are relati ve t o 
tirze pati de d osi n g .  
I m m u n o ge nicit y 
Sa m ples P P P X
P har mac o ge netics P
A b bre viati o ns:  C R U = cli nical researc h u nit; C- S S R S = C ol u m bia -S uici de Se verit y Rati n g Scale; E C G = electr ocar di o gra m; E D = earl y disc o nti n uati o n; 
P = pr e d ose; P H Q -9 = Patie nt Healt h Q uesti o n naire -9; P D = p har mac o d y na mics; P K = p har mac o ki netics ; S H F F = Self -Har m F oll o w -U p F or m; 
S H S F =Self -Har m S u p ple me ntar y F or m ; S M P G = self -m o nit ori n g of plas ma gl uc ose . 
N ote:  Site s h o ul d sc he d ule pr oce d ures per as a p pr o priate .  H o we ver, if m ulti ple pr oce d ures ta ke place at t he sa me ti me p oi nt, t he f oll o wi n g or der of t he 
pr oce d ure s h o ul d be use: E C G, vital si g ns, P K / P D sa m ples, gl uc ose sa m ples, i m m u n o ge nicit y, cli nical la b orat or y sa m ples a n d st ora ge sa m ples .U nless 
ot her wise s pecifie d, pre d ose sa m ples a n d pr oce d ure ma y be c ollecte d or perf or me d a n y ti me o n t he sa me da y pri or t o d osi n g. A 1 0 % ti me all o wa nce varia nce 
will be c o nsi dere d acce pta ble f or aceta mi n o p he n a n d tirze pati de P K sa m pli n g. 
aFi nal f oll o w -u p will occ ur o n Da y 6 4±1 da y (i.e. 2 8 da ys ±1 da y after fi nal tirze pati de d ose ). Earl y disc o nti n uati o n visit s h o ul d ta ke place wit hi n [ADDRESS_117011] disc o nti n ues pri or t o recei vi n g a 
d ose of tirze pati de. 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 15
LY32981763.Introduction
3.1. Study Rationale
Tirzepati de(LY3298176) is a dual glucose -dependent insulinotropic pept ide(GIP) and 
glucagon -like peptide 1 (GLP -1)receptor agonist being devel oped as an adj unct to di et and 
exercise for chroni c weight m anagement in adult patients wi th or wi thout type 2 di abetes 
mellitus (T2DM) who have an init ial body  mass index (BMI) of 30kg/m 2or greater (obese) or
27 kg/m 2or greater (overweight) .  The impact of tirzepati de on gastri c empt ying (GE) has been 
assessed in healthy subjects and in patients with T2DM using acetaminophen pharmacokinet ics 
(PK) as a surrogate (Study  I8F-MC-GPGA ).  Howeve r, data on the GE effects of tirzepat ide in 
overwei ght/obese non -diabet ic subjects are presently lacking.
Study  I8F-MC-GPHU (GPHU) will assess the effect of mult iple doses of tirzepatide (5 to 15 mg) 
on the PK of acetaminophen to determine the impact on gastric empt ying, and the 
pharmacodynamics (PD), safet y and tol erabilit y of tirzepat ide in overwei ght/obese non-diabet ic
subjects and overwei ght/obese T2DM subjects when administered using a prefilled syringe 
(PFS) .
3.2. Background
The available preclinical and clinical data indicate that co -stimulation of GIP and GLP -[ADDRESS_117012] of selective GLP -1receptor stimulat ion (Frias et al. 2018; Coskun et al. 2018).
Tirzepati de, a dual  agonist of GIP and GLP -1, is a 39 -amino acid synt hetic pept ide.  It is 
administered once weekly by [CONTACT_6567] ( SC)inject ion.  Its structure is based on the GIP 
sequence and includes a C20 fatty  di-acid m oiety that prol ongs the durati on of action.  It has a 
chemical structure and pharmaco logic profile that is di stinct fro m the GLP -1 receptor agonists 
due to the addition o f GIP, whi ch is unique amo ng the marketed incret in mimet ics.
In a Phase I study  (Coskun et al . 2018) that included sing le and mult iple ascending dose (SAD, 
MAD) parts, tirzepat ide has been administered as single SC doses up to 8 mg in healt hy subjects.  
In the MAD part, higher doses up to 10 mg were attained in healt hy subjects via dose escalat ion.  
Doses up to 15 mg were achieved in pat ients with T2DM via dose escalat ion.  In thi s study , 
gastrointestinal (GI) adverse events (AEs) (nausea, vomit ing, di arrhea, abdo minal distensio n) 
and decreased appetite were the most frequently reported events by  [CONTACT_105409] T2DM and were dose related.  Most AEs were mild in severit y, a few were 
moderate, and none were reported as severe.  During the single ascending dose study , the hi gh 
incidence of GI AEs, notably vo miting, were considered to be dose limit ing at the 8 -mg dose; 
therefore, the [ADDRESS_117013] ive GLP -1 receptor agoni sts. 
Immunogenicit y assessment sin Phase I showed low treatment -emergent anti drug ant ibody  
(TE-ADA) rate in tirzepatide -treated subjects (2.6%).  Highest ADA titers in TE -ADA+ subjects 
ranged fro m 1:40 to 1:[ADDRESS_117014] on tol erabili ty or PK profile of t irzepat ide.  A 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e 1 6 
L Y 3 2 9 8 1 7 6 fe w s u bjects e x perie nce d tra nsie nt ele vat i o ns i n li pase a n d/ or a m ylase le vels, b ut t hese e pis o des 
were n ot ass ociate d wit h a n y  rele va nt o utc o m es.  O nce -wee kl y d oses of 1, 5, [ADDRESS_117015] u d y  ( Frias et al , 2 0 1 8).  A n a d dit i o nal d ose 
le vel of [ADDRESS_117016] u g i nteracti o ns ( D DIs) 
t h at ma y  b e n ote d c o ul d be lar gel y attri b ute d t o t he i nfl ue nce of tirze pat i de o n G E w hic h i n t ur n 
c o ul d al ter t he a bs or pti o n of  c o m m o nl y  c o -a d mi nistere d me dicat i o ns a d mi nistere d via oral r o ute. 
I n healt h y s u bjects a n d patie nts wit h T 2 D M, c ha n ges i n t he mea n c o nce ntrati o n -ti me pr ofiles of 
aceta mi n o p he n s u g geste d a d ose- de pe n de nt dela y i n G E f o ll o wi n g a si n gle d ose of tirze pat i de. 
T he dela y i n G E res ulte d i n a 5 0 % decrease i n Cm a x a n d a p pr o xi matel y a 1- h o ur dela y i n tm a x . 
T he o verall A U C was n ot affecte d. T he dela y i n G E was greatest f o ll o wi n g t he first d ose of 
ti rze pat i de (at d ose le vel ≥1. 5 m g) a n d a p peare d t o s h o w tac h y p h yla xis after re p eate d d osi n g. 
F urt her details ca n be f o u n d i n t he I n vesti gat or’s Br oc h ure (I B). 
T he i m pact of  ti rze pat i de o n G E dela y a n d tac h y p h yla xis after re peate d d osi n g was si milar 
bet wee n healt h y v o l u nt eers a n d patie nts wit h T 2 D M (i ncl u di n g s o me w h o were o ver wei g ht) 
base d o n P hase [ADDRESS_117017] of  tirze pat i de o n G E dela y i n n o n -dia bet ic s u bjects 
w h o are o bese/ o ver wei g ht ha sn ot bee n deter mi ne d. 
3. 3. B e n efit/ Ri s k A s s e s s m e nt 
Ris ks of t ir ze pat i de ha ve bee n c o nsiste nt wit h ris ks ass o ci ate d wi t h  ot her G L P -1 rece pt or 
a g o nists c urre ntl y  m ar kete d.  P ote nti al  ris ks i ncl u de, b ut are n ot li mite d t o, GI effects, ac ute 
pa ncreat itis ( v er y  rare) , i ncreases i n heart rate, a n d h y p o gl yce mic e ve nts ( G L P -[ADDRESS_117018]). 
N o cli nicall y  si g nifica nt safet y or t ol era bilit y c o ncer ns h a ve bee n i de ntifie d d uri n g cli nical 
i n vesti gat i o n of t ir ze pat i de u p t o t he si n gle d ose le vel of 5 m g or m ult i p le wee kl y d oses, w he n 
escalate d u p t o 1 5 m g.  Base d o n t his i nf or mati o n, t he 6wee kl y d oses of 5 t o 1 5 m g/ 0. 5 m L 
ti rze pat i de ( 5/ 5/ 1 0/ 1 0/ 1 0/ 1 5 m g ) t o be a d mi nistere d i n t his st u d y  are reas o na bl y  a nt ic i pate d t o be 
t ol era ble i n t his gr o u p of s u bjects .
Base d o n t he k n o w n p har mac o l o g y  of  ti rze pat i de, o ver wei g ht/ o bese n o n- dia bet ic s u bjects ma y 
be nefit fr o m wei g ht re d ucti o n .  I n a d dit i o n, t he refere nce s u bjects wit h T [ADDRESS_117019] u d y  treat me nts, i ncl u di n g i m pr o ve d gl yce mic c o ntr ol a n d re d uce d 
b o d y  wei g ht.  
M ore i nf or mat i o n a b o ut t he k n o w n a n d e x pecte d be nefits, ris ks, seri o us a d verse e ve nts ( S A Es) 
a n d reas o na bl y a nt ic i pate d A Es of  ti r z e pat i de are t o be f o u n d i n t h e I n vesti gat or’s Br oc h ure I B .C CI 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e [ADDRESS_117020] ti me p oi nt wit h a 
meas ura ble c o nce ntrati o n (A U C 0-t last ), ti m e 
of  m a xi m u m  o bser ve d dr u g c o nce ntrati o n 
(tma x ), ma xi m u m o bser ve d dr u g c o nce ntrati o n 
( C ma x )
Sec o n d ar y 
T o e val uate ti rze pat i de P K a n d P D effects 
f o ll o wi n g m ult i p le d oses of S C ti rze pat i de in 
o ver wei g ht/ o bese n o n- dia bet ic s u bjects a n d 
o ver wei g ht/ o bese T 2 D M s u bjects 
T o e val uate ti rze pat i de safet y a n d t ol era bili t y  
f o ll o wi n g m ult i p le d oses of S C ti rze pat i de i n 
o ver wei g ht/ o bese n o n- dia bet ic s u bjects a n d 
o ver wei g ht/ o bese T 2 D M s u bjects Gl yce mic c o ntr ol ( plas ma gl uc ose , H b A 1c ), 
a n d tirze pati de area u n der t he c o nce ntrati o n 
vers us ti me c ur ve fr o m t i me zer o t o i nfi nit y 
(A U C 0- ∞ )A U C [ADDRESS_117021] ci rc u mfere nce , a p peti t e 
V A S sc ores 
A b br e viati o ns:  A U C 0- ∞ = area u n der t he dr u g c o nce ntrati o n -ti me c ur ve fr o m zer o t o i nfi nit y; 
Cma x =ma xi m u m o bser ve d dr u g c o nce ntrati o n; P K =p har mac o ki netics; S C = s u bc uta ne o us d ose; 
tma x =ti me t o ma xi m u m c o nce ntrati o n ; V A S = Vis ual A nal o g Scale. C CI 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e [ADDRESS_117022] u d y i n o ver wei g ht/ o bese n o n- dia bet ic s u bjects a n d 
o ver wei g ht/ o bese T [ADDRESS_117023] ace o n Da ys 8 ( ± 1 da y) , 1 5 ( ± 1 da y ), 2 2 ( ± 1 da y ), 2 9 ( ± 1 d a y ), a n d 
4 3 ( ± 2 da ys) .
A fi nal f o ll o w- u p visi t will occ ur o n Da y 6 4 ± 1 da y (i.e. 2 8 da ys ± 1 da y  af t er t h e fi nal 
ti rze pat i de d ose ). 
St u d y  g o ver na nce c o nsi derati o ns are descri be d i n detail i n A p pe n di x [ADDRESS_117024] u d y  desi g n. 
A b bre viat i o ns:   G E = gastric e m pt yi n g; P K = p har mac o ki net ic s. 
Fi g ur e G P H U . 1. Ill u str ati o n of st u d y d e si g n f or Pr ot o c ol I [ADDRESS_117025] i vit ies ( Secti o n 2). C CI 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117026] ivities(Secti on 2).
5.2. Number of Participants
Approximately  [ADDRESS_117027] scheduled procedure shown in the Schedule o f 
Activities(Secti on 2) for the last subject/ pati ent.
5.4. Scientific Rationale fo r Study Design
This study  will be open -label as the study  primary  endpoin t PK m easures are obj ective rather 
than subject ive.  This study  is designed to assess the effect of mult iple doses of tirzepat ide (5 to 
15 m g/0.5 mL) on gastric empt ying and the PD, s afety and tol erabilit y of t irzepat ide in both 
overwei ght/obese nondiabet icsubjects and overweight/obese T2DM subjects .  
Acetaminophen is 
selected as the study  probe drug as i t is a well -established marker for the rate and extent of 
gastri c empt ying (Young 2005 ).  A delay in gastric emptying is reflected in the alterations to the 
concentration -time profile of acetaminophen
The dose justificat ion for tirzepat ide is provided in Section 5.5(Justificat ion of Dose) .
The rati onale for the sample size is provided in Secti on 10.1 (Sample Size Determinat ion).
5.5. Justification for Dose
The ti rzepat ide doses of [ADDRESS_117028] been selected based on current 
preclinical pharm
acology, toxi cology,and clinical data; 15mg SC Q W is the highest 
maintenance dose planned for evaluat ion in the Phase [ADDRESS_117029] dose (5 mg on Day 1) and after the first m aximum  dose (15 mg on Day 36) of  
tirzepat ide.  The highest dose of [ADDRESS_117030] l evel doses in 6 -mont
h monkey and rat toxico logy 
studi es, respectively.  Addit ional inform ation canbe found in the IB.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 20
LY32981766.Study  Population
Eligibilit y of subjects for the study  will be largely based on the results of medical history , 
physical examinat ion, vital signs , clinical laboratory tests and 12-lead electrocardi ogram  (ECG). 
The nature of any condit ions present at the time of the physical examinat ion and any preexist ing 
condi tions will  be docum ented.
Screening may occur up to 
[ADDRESS_117031]’ s visi t may be 
rescheduled, and any  assessments or procedures performed up to that point may be repeated to 
confirm their eligibilit y.  
Prospective approval o f protocol  deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
6.1. Inclusion Criteria
Subjects are eligible for inclusio n in the study  only if they  meet all  of the f ollowing criteria at 
screening:
Subject Characteristics
[1]Are overwei ght or obese ( body  mass index [BMI] of 27 kg /m2to 45 kg /m2, 
inclusive )
[1a] nondiabet icmale or female subjects, as determined by [CONTACT_9870] ,
physical examinat ion, and safety laboratory  assessments at screening
[1b] diabeticmale or female subjects as determined by [CONTACT_9870]
Have a diagnosis of T2DM for at least 1 y ear
Have T2DM controlled wit h diet and exercise alo ne or are onastable 
dose of metformin for at least 3 m onths
Have a hemoglo bin A1c value at screening of ≥7.0% and ≤10.0 %
Have a self -reported change in body  weight of not m ore than ± 5 
kg 
within 3 m onths prior to screening
[2] H ave safety laboratory  test resul ts wi thin norm al reference range or with 
abnorm alities deemed clinically  insignificant by  [CONTACT_3170]
[
3] H ave venous access sufficient to allow for blood sampling as per the p rotocol
[
4] M ale or female subjects between the ages of 18 to 65years, inclusive;
[
4a]Male subjects :
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 21
LY3298176men, regardless of their fert ility status, wi th nonpregnant wom an of 
childbearing potential (WOCBP) partners must agree to either remain 
abstinent (if this is their preferred and usual lifest yle) or use condoms 
plus [ADDRESS_117032] ive (less than 1% failure rate) method of 
contraception (such as co mbination oral contraceptives, implanted 
contraceptives, or intrauterine device) or effect ive method of 
contraception, (such as diaphragms with spermicide or cervical sponge) 
for the durati on of  the stud y and for [ADDRESS_117033] ion .  
omen and their partners may choose to use a double -barrier method 
of contracepti on.  (Barri er protecti on methods wi thout concomi tant 
use of a spermicide are not an effect ive or acceptable method of 
contraception.  Thus, each barrier method must include use of a 
spermicide.  It should be noted however that the use of male and 
female condo ms as a double -barrier m ethod is not considered 
acceptable due to th e high failure rate when these barrier methods 
are combined.)
operiodic abst inence (e .g., calendar, ovulat ion, symptothermal, 
postovulat ion methods), declarat ion of abst inence just for the 
durati on of  a study , and wi thdrawal  are not acceptable methods of 
contraception.
men with pregnant partners should use condo ms during intercourse for 
the duration of the study  and unt il the end of est imated relevant potential 
exposure in WOCBP, which corresponds to [ADDRESS_117034] ion.  
men must agree to ref rain fro m sperm  donati on for the durati on of  the 
study  and until their plasma concentrations are below the level that could 
resul t in a relevant potential exposure to a possible fetus, predicted to be 
[ADDRESS_117035] ion.
men who are in exclu sively  same -sex relati onships (as thei r pref erred 
and usual lifest yle) are not required to use contraception.
[
4b]Femalesubjects :
wom en of childbearing potential (WOCBP) who are abst inent (if this is 
complete abst inence, as their preferred and usual lifest yle) or in a 
same -sex rel ationship (as part of their preferred and usual lifestyle) must 
agree to either remain abst inent or stay in a same -sex relati onship 
without sexual relat ionshipswith males.  Periodic abstinence (e .
g., 
calendar, ovul ation, symptothermal, post -ovulation methods), 
declaration of abst inence just for the duration of a study, and withdrawal 
are not acceptable methods of contraception.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 22
LY3298176otherwi se, WOCBP participating mus t agree to use effect ive 
contraception, where at least 1 form is highly effective (less than 1% 
failure rate), for the ent irety of the study .  Contracepti on m ust continue 
following co mpletion of IP administration for [ADDRESS_117036] ive (less than 1% failure rate, such as combinat ion 
oral contraceptives, implanted con tracepti ves or intrauterine 
devices) will be used.  Effect ive contraception (such as male or 
female condo ms with sperm icide, diaphragms wit h spermicide or 
cervical sponges) may be used as the second therapy .  Barri er 
protecti on m ethods wi thout concomi tant use of a spermicide are 
not an effect iveor acceptable method.  Thus, each barrier method 
must include use of a spermi cide (that is, condom  with spermicide, 
diaphragm  with spermicide, female condom with spermicide).  It 
shoul d be noted that the use of male and female condo ms as a 
doubl e barri er method i s not considered acceptable due to the high 
failure rate when these me thods are combined.
oMust not be breastfeeding
wom en who are not of childbearing potential may participate and 
include those who are:
oinfertile due to surgical sterilizat ion (hysterectomy, bilateral 
oophorectomy , or tubal  ligation), congenital ano maly such as 
mullerian agenesis, or
opostm enopausal –defined as eit her
i. a wom an at l east [ADDRESS_117037] 1 y ear wi thout an al ternat ive medical cause, AND a 
follicle -stimulat ing horm one (FSH) >40 m IU/mL; wom en 
in this category  must test negative in pregnancy  test pri or to 
study  entry
ii. a wom an [ADDRESS_117038] 12 months of spontaneous amenorrhea; or
iii. a wom an 55 y ears or ol der wi th a diagnosis of menopause 
prior to starting hormone replacement therapy .
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 23
LY3298176Informed Consent
[5] A re reliable and willing to make themselves available for the duration of the 
study  and are willing to follow study  procedures
[
6] Arewilling and a ble to parti cipate in the di etary  intervent ion part of the study , 
in the opi[INVESTIGATOR_3078] n of the invest igator
[
7] H ave given written informed consent approved by [CONTACT_105410]  
(Lilly )and the institutional review board (IRB ) governing the site
6.2. Exclusion Criteria
Subject s will be excluded fro m study  enro llment if they meet any o f the following cri teria at 
screening :
Medical Conditions –General
[
8] Have a history  or current CV(for example, acute myocardial  infarct ion, 
congest ive heart failure, unstable angin a, uncontrolled hypertensio n [systolic 
blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg], 
cerebrovascular accident [including transient ischemic attack] , venous 
thromboembo lis, etc), respi[INVESTIGATOR_696] , hepati c, renal , GI, endocrine, hematol ogical 
(including history  of thrombocy topeni a), or neurologi cal disorders capable of 
significant ly altering the absorpti on, m etabo lism, or eliminat ion of drugs ;or
constituting a risk when taking the IP;or may interfer ewith the interpretati on 
of data
[
9] Have obesit y induced by  [CONTACT_105411] (for example, 
Cushing Syndrome) or diagnosed monogenet ic or syndro mic forms of obesit y 
(for example, Melanocortin 4 Receptor deficiency or Prader Willi Syndro me)
[10] Have acute or chronic pancreat itis or a history  of acute i diopathic pancreati tis; 
or have other GI disorder s(for example, relevant esophageal reflux or gall 
bladder disease) that coul d be aggravated by  [CONTACT_34046] -1 analogs ; subjects w ho had 
cholecysto lithiasis (gall stones) and/or cholecystectomy (rem oval of gall 
bladder) in the past, with no long-term com plicat ions, are eligible for 
participat ion
[11] H ave a known clinically significant gastric empt ying abnormalit y (e. g., gastri c 
outlet obstructi on)
,have undergone weight loss surgery  such as gastri c by[CONTACT_6476] 
(bariatric) surgery or restri ctive bariatric surgery (e .g., Lap -Band ®), or have 
endoscopi c and/or devi ce-based therapy  for obesi ty or have had device 
removal within the l ast 
6months (for example, mucosal ablat ion, gastric 
artery  embo lization, intragastric balloon and duodenal- jejunal by[CONTACT_17991])
[12] H ave a personal or family history  of medullary  thyroi d carcino ma (MTC), 
have mult iple endocrine neoplasia syndro me type 2 (MEN 2), or ca lc
itonin 
≥20pg/m L at screening
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 24
LY3298176[13] Have confi rmed type 1 di abetes m ellitus, or a history  of ketoaci dosis, or 
hyperosmo lar state/coma
[14] H avefindings in the 12 -lead ECG at screening that, in the opi[INVESTIGATOR_3078] n of the 
investigator, may increase the risks of potentially clinically  relevant 
worsening associ ated wi th parti cipat ionin the study
[
15] Have an act ive or untreated malignancy or have been in remission fro m a 
clinically significant malignancy (other than basal or squamous cell skin 
cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for <5 years 
prior to screening
[
16]Have e vidence of human immunodeficiency  virus (HIV) and/or posi tive HIV 
antibodies at screening
[17] Have e vidence of hepatit is B or posit ive hepat itis B surfa ce ant igen and/or 
evidence of hepat itis C virus (HCV) or hepatit is C antibody  with confi rmed 
presence of 
hepat itis C virus ribonucleic acid (RNA) at screening (a positive 
HCV ant ibody  at screening will nee d an addit ional HCV RNA 
assay –detectabl e HCV RNA means a subject will meet exclusio n criteria)  
Subjects with a previous diagnosis o f HCV who have been treated with 
antiviral therapy  and achieved a sustained viro logical  response m ay be 
eligible for inclusio n in the study, provided they have no detectable HCV 
RNA on the screening HCV polymerase chain reaction test.  A sustained 
virological response is defined as an undetectable HCV RNA level 24 
weeks after completion o f a full, documented course of an approved 
antiviral therapy  for HCV.
Subjects who have spontaneously cleared HCV infection, defined as (1):  a 
positive HCV ant ibody  test and (2):  a negative HCV RNA test, with no 
history  of anti-HCV treatm ent, m ay be eligible for inclusio n in the study , 
provi ded they  have no detectable HCV RNA on sc reening for this study .
[18] Have serum aspartate aminotransferase (AST) or alanine aminotransferase 
(ALT) >2. 0 
×the upper limit of normal ( ULN )or total  bilirubin (TBL) 
>1.5 ×ULN ; (except for subjects with Gilbert’s syndro me, which can be 
enrolled with TBL <2.0× ULN), or alkaline phosphatase (ALP) >1.5× ULN;
subjects wi th nonalcoho lic fatty liver di sease are allowed to part icipate
[19] Have had a b lood donati on of  [ADDRESS_117039] month prior to sc reening
[20] H ave a history  of drug or al coho l abuse or a posi tive drug screen (unless the 
positive testing is due to a drug prescribed to the subject by a healt h care 
professio nal); and/or smoke >10 cigarettes per day or the equivalent; or are 
unable or u nwilling to refrain fro m nicotine use during CRU admissio n
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 25
LY3298176[21]Have had a blood transfusio n or severe blood loss within the last [ADDRESS_117040] 
a hemoglo bin value <11 g/dL (males) or <10 g/dL (females), or any  other 
condi tion known to interfere with hem oglobin A1c measurement
[22] H ave an average weekly  alcoho l intake that exceeds 21 units per week (males) 
and 14 units per week (females) (1 un it = 12 oz or 360 mL of beer; 5 oz or 
150
mL of wine; 1.[ADDRESS_117041] illed spi[INVESTIGATOR_17040] s), or are unwilling to stop 
alcoho l consumpt ion from admissio n to the CRU and until discharge fro m the 
study  or com pletion of all study  procedures
[23] H ave a history  of atopy  or clinically  significant m ultiple or severe drug 
allergies, or severe posttreatment hy persensi tivity reacti ons (including, but not 
limited to, ery thema m ultiforme maj or, linear immunogl obulin A dermatosis, 
toxic epi[INVESTIGATOR_77116], or exfoliat ive dermat itis)
[
24] Impaired renal  estimat ed glo merular filtration rate <60 mL/min/1.[ADDRESS_117042] m ay be 
perform ed in case of an init ial borderline resul t <60 mL/min/1.[ADDRESS_117043] value fro mthe 2 tests will be accepted
Prior/Concomitant Therapy –General
[25] Have been treated with prescription drugs that promote weight loss (e. g., 
sibutramine, mazindo l, phentermine, naltrexone/bupropi[INVESTIGATOR_2394], liraglut ide) or 
similar other BWloss medicat ions, including over -the
-counter medic ations 
(e.g., Alli®)within 6 months prior to screening or between screening and 
enrollment
[26] Have received chronic (last ing >14 consecut ive days) systemic glucocortico id 
therapy  (excluding topi [INVESTIGATOR_2855], intra -articular, and inhaled preparations) within 
1mont
h before screening, or betw een screening and enrollment
[27]Have been treated with:
[27a] Non -diabetic subjects : any glucose -lowering agent during th elast 
3months pri or to screening or between screening and enrollment
[27b] T2DM subjects : have taken any glucose -lowering medications other 
than metformin any t ime during the last 3 months before screening or during 
the screening/lead -in period; short -term use of insulin (<14 days) for treatment 
of acute condi tions is all owed in the 3 -month peri od pri or to entry  and after 
enrollment
[28] Have received treatment with a drug that has not received regulatory  approval  
for any  indicati on wi thin 30 days or 5half-lives (whichever is longer) of 
screening
Prior/Concurrent Clinical Trial Experience
[29] A re perso ns who have previously co mpleted or withdrawn fro m this study
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 26
LY3298176[30] H ave previ ous exposure or known allergies to t irzepatide or related 
compounds
[31]Are current ly enrolled in a clinical study  involving an IP or any other type of 
medical research judged no t to be scient ifically or medically co mpat ible with 
this study .
Exclusions Applicable Only to T2DM Subjects
[
32] Have had more than 1 epi[INVESTIGATOR_66677], as defined by [CONTACT_105412], wi thin 6 m onths before screening or 
has a history  of hypoglycemia unawareness or poor recognit ion of 
hypoglycemic symptoms; any patient that cannot communicate an 
understanding of hypoglycemic symptoms and the appropriate treatment of 
hypoglycemia prior to the first dose of stu dy drug shoul d also be excluded
[
33] Have a history  of proliferat ive retinopathy or maculopathy as determined by 
[CONTACT_105413] a recent (<6 mon ths) ophthalmo logic examinat ion
Other Exclusions
[
34] Have any lifet ime history  of a sui cide attem pt
[35]Have a Patient Health Questionnaire -9 (PHQ -9) score of 15 or more at 
screening
[36]On the Columbia -Suicide Severi ty Rating Scale (C -SSRS) at screening:
a “yes” answer to either Question 4 (Act ive Suicidal Ideation wit h Som e 
Intent to Act, Without Specific Plan) or
a “yes” answer to Question 5 (Act ive Suicidal Ideation with Specific Plan 
and Intent) on the “Suicidal Ideat ion” portion of the C -SSRS, or
a “yes” answer to any  of the suici de-related behaviors (Actual Attempt, 
Interrupted Attempt, Aborted Attemp t, Preparatory Act or Behavior) on 
the "Sui cidal  Behavi or" porti on of  the C -
SSRS, and
the ideati on or behavior occurred within the past month
[37] A re invest igative site personnel direct ly affiliated with this study  and thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logical or legally adopted ;
[
38] A re Eli  Lilly and Com pany empl oyees;
[
39] Are deemed unsuitable by [CONTACT_92355] .
6.3. Lifestyle and/or Dietary Requirements
Throughout the study, subjects may undergo medical assessment sand review of compliance with 
requirements before continuing in the study .
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117044] samples are taken  (see 
Schedule of Act ivities
 [Secti on 2]). A meal will be offered to study subjects after about [ADDRESS_117045] tirzepat ide dose .  On the day of gastric em ptying evaluat ion, a meal will be given about half 
an hour before the scheduled  acetaminophen dose in order to assess gastric empt ying (see 
Schedule of Act ivities [Section 2]).  The m acronutri ent com position (i.e. number of grams of 
carbohydrate, fat and protein) 
of this meal for each subject shoul d be consistent on all gastric 
emptying procedure days and the am ount consum ed m ust be recorded in the subject’s CRF .  For 
T2DM pati ents, the m orning dose of metformin ma y be taken together with this meal if 
applicable. 
 During inpat ient stay s, subjects may not consume any  food other than that provided 
by [CONTACT_47365], although water may be consumed freely
.
6.3.2. Caffeine, Alcohol, and Tobacco
No al coho l and nicotine use will be per mitted while the subject is resident in the CRU.  While 
not resi dent in the CRU, subjects must consume no more than 10 cigarettes or the equivalent per 
day and alcohol  consumption should be limited to approximately 3 units daily for m ales and 
2 units daily for females, as defined in Exclusion Criteria [22].
Subjects will be 
allowed to maintain their regular caffeine consumpt ion throughout the study 
period (except during specific fast ing time periods) .
6.3.3.
 Activity
No strenuous phy sical act ivity will be allowed for 48 hours pri or to tirzepat ide dosing on Day 1 
until completion of all study  procedures .
6.4. Screen Failures
Screening tests such as clinical laboratory tests and vi tal signs/ECGs may b e repeated at the 
discreti on of
 the invest igator .  Individuals who do not meet the criteria for participat ion in this 
study (screen failure) may not be re -screened .  Subject numbers/enrollment numbers are assigned 
on Day
 -2 of the Baseline Period to ensure only eligible subjects enter the study .
LY3298176
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117046] ered
Subjects will receive t irzepat ide SC QW alo ne for 6 weeks on Day s 1, 8, 15, 22, 29, and 36, and 
will receive oral acetaminophen on Days -1, 2, and 37.   Acetaminophen may be administered 
with water and dosing cups or sy ringes shoul d be flushed wi th water to ensure the complete dose 
is delivered.
Table GPHU .2shows the treatment sadministered .
Table GPHU .2. Treatment sAdministered
Treatment Name [CONTACT_105433]5 mg / 0.5 ml; 10 mg/0.5 ml; 15 mg/0.5 ml 160mg/5 mL
Route of 
AdministrationSC Oral
Dosing 
instructionsSC QW into abdominal quadrant Single dose of 31.3 mL to be taken orally
Abbreviations:  QW = once weekly; SC = subcutaneous.
The investigator or designee is responsible for:
explaining the correct use of the investigational product (IP) to the site personnel 
verifying that instructions are fo llowed properly
maintaining accurate records of IPdispensing and collect ion
and returning all unused medic ation to Lilly or its designee at the end of the study
Note : In some cases, sites may destroy  the m aterial  if, during the invest igativesite select ion, the 
evaluator has verified and documented that the site has appropriate facilit ies and wri tten 
procedur es to dispose of clinical materials .
Site staff will administer all inject ions.  Detailed instructions for will be provided by  [CONTACT_456] . 
All injecti ons will be administered into the SC tissue of the abdominal wall, wit h injection sites 
alternated week ly between 4 sites, that is, right and left upper quadrants and right and left lower 
quadrants. Only a limi ted number of individuals will perform SCadministration for consistency
reasons. Dosing will ideally occur at approximately the same time of day i n all dose 
cohorts. The actual t ime of dosing will be recorded in the patient’s electroni c case report form 
(eCRF).
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 29
LY32981767.1.1. Packaging and Labeling
Tirzepati de will  be supplied by  [CONTACT_11007] .  Tirzepat ide will be provided as prefilled sy ringes
containing 0.5 mL solution and provided in individual cartons to be dispensed.   
The IP will be labeled according to the country’s regulatory  requi rements.
Commercially available liquid acetaminophen will be site sourced.
7.2. Method of Treatment Assignment
All subjects will re ceive the same treatm ent
7.2.1. Selection and Timing of Doses
The doses will be administered at approximately the same t imeon each dosing day.  The actual  
time of all dose administrations will be recorded in the subject ’s eCRF.
7.3. Blinding
This is an open -label study .
7.4. Dose Modification
Dose m odificat ion is not permitted in this study .
7.5. Preparation/Handling/Storage/Accountability
The invest igator or designee must confirm appropriate temperature condit ions have been 
maintained , as communicated by [CONTACT_2728], during transit for all IPreceived and any 
discrepancies are reported and resolved before use of the study  treatm ent.
Only participants enro lled in the study  may receive IPor study materials, and only authorized 
site staff may supply or administer IP. All IPshould be stored in a nenvironmentally controlled 
and mo nitored (m anual  or autom ated) area in accordance wit h the labeled storage condit ions 
with access limited to the invest igator and authorized site staff .
The invest igator is responsible for study treatm ent accountabilit y, reconciliat ion, and record 
maintenance ( such as recei pt, reconciliat ion and final disposit ion records) .
7.6. Treatment Compliance
Tirzepati de and acetaminophen will be administered at the study  site and docum entati on of  
treatm ent admin istrati on will occur at the site.
7.7. Concomitant Therapy
In general, concomitant medicat ion shoul d be avo ided.  If the need for concomitant medication 
arises (for exam ple, to treat an AE), inclusio n or continuat ion of the subject may be at the 
discreti on of  the invest igator, preferably after consultation with a Lilly Clinical Pharmaco logist 
(CP) or CRP or designee.  Any  medicati on used during the course of the study  must be 
docum ented.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117047] received 
or be permitted to receive short -term (<14 days) insulin wit hin 3 months prior to study  entry  
and/or after enrollment .
The ti rzepat idedose escalat ion scheme shave been designed to reduce the development of 
intolerable GI symptoms .  During the dose escalat ion period, every effort should be made by [CONTACT_105414] m aintain subject s on the tirzepat ide dosage .
To mit igate GI symptoms and manage subject s with poorly toleratedGI AEs, the i nvest igator 
shoul d:
Advise subject s to eat smaller meals, for example, splitt ing 3 daily  meals into 4 or m ore 
smaller meals, and to stop eating when they  feel full.
Prescribe symptomat ic med ication (f or example, approved anti-emet ic or anti -diarrheal 
medicat ion)
7.8. Treatment after the End of the Study
Not applicable.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 31
LY32981768.Discontinuation Criteria
Subjects discont inuing fro m the treatm entor study prematurely for any reason shoul d complete 
adverse event and other follow -up procedures per Section 2(Schedule of Act ivities).
8.1. Discontinuation from Study Treatment
8.1.1. Permanent Discontinuation from Study Treatment
Possible reasons leading to permane nt discontinuatio n of IP :
The subject/ patient requests to discont inue IP
If asubject/ patien t is inadverten tlyenrolledand it is determine dthatcontinued treatment
with studydrugwould not bemedically  appropri ate (Secti on 8.1.2 Discont inuat ion of 
Inadvertent ly Enrolled Subjects )
If a subject is diagnosed with acut e orchroni cpancrea titisafter enrollment
If a subject i s confirmed to have developed T1DM after enrollment
Ifa subject is diagnosed withMTC after enrollment
If asubject i sdiagnose dwith an activ e oruntreated malignanc y(othe rthan basa l or
squamou scellskin cancer, in situ carcino mas of the cervix, or in situ prostat ecancer )
afterenrollment
If the invest igator, after consultation with the sponsor -designated medical monitor, 
determines that a systemic hypersensit ivity reaction has occurred related to st udy drug 
administration, the participant should be permanently discontinued from the 
invest igational drug. 
If a subject is diagnosed wit h any other TEAE, SAE, or clinically  significant l aboratory
value for which the invest igator bel ieves that permanent IP discontinua t ion is the 
appropriate measure to be taken
Iffemalesubject becomes pregna nt
Discontinuati on of  the IPfor abnormal liver tests should be considered by [CONTACT_47548] 
a patientmeets 1 of the fo llowing condi tions af ter consul tation wi th the Lilly designated medical 
monitor:
ALT or AST >8× ULN 
ALT or AST >5× ULN sustained for more than 2 weeks
ALT or AST >3× ULN and(TBL >2× ULN orinternat ional norm alized rati o >1.5)
ALT or AST >3× ULN, with the appearance of fatigue, nausea, vo miting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%) .Drug -related vo miting 
requi ring intravenous (IV) hy dration treatment or causing severe distress (prevents daily 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 32
LY3298176activit ies and results in no appeti te, or requi res an em ergency depart ment visit, or 
hospi [INVESTIGATOR_28689]), that cannot be resolved by  [CONTACT_105415] .
Subjects who discont inue IP early will be also di scontinued fro m the study  after performing the 
EDvisit and safet y follow-up visit procedures, as specified in Section 2(Schedule ofActivit ies).
8.1.2. Discontinuation of Inadvertently Enrolled Subjects
If the Sponsor or invest igator ident ifies a subject who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discussio n must occur between the Lilly  clinical pharmacol ogist/CRP
and the invest igator to determine if the subject may continue in the study .  If both agree it is 
medically appropriate to continue, the invest igator must obtain documented approval fro m the 
Lilly clinical pharmaco logist/CRP to allow the inadvertent ly enro lled subject to continue in the 
study  with or wi thout continued treatment with IP.  
8.2. Discontinuation from the Study
In addit ion to the situations that result in IP discontinuat ion described in Sect ion 8.1.1
(Perm anent Di scontinuati onfrom Study  Treatm ent), subjects will be di scontinued in the 
following circumstances:
Enrollment in any other clinical study  involving an IPor enrollment in any other ty pe of 
medical research judged not to be scient ifically or medically co mpat ible with this study
Parti cipation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicable laws, r egulations, and GoodClinical Pract ice
Invest igator Decisio n
othe invest igator decides that the subject shoul d be discontinued from the study
oif the subject , for any  reason, requi res treatment with another therapeutic agent 
that has been demo nstrated to be effect ive for treatment of the study  indicat ion, 
discontinuat ion from the study  occurs pri or to introducti on of  the new agent
Subject Decisio n
othe subject ,or legal representative ,requests to be withdrawn from the study .
8.3. Subjects Lost to Follow -up
A subject will be considered lost to follow -up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  [CONTACT_4145].  Site personnel are expected to make 
diligent attempts to contact [CONTACT_105416] a scheduled visit or were otherwise 
unable to be fo llowed up by  [CONTACT_4179].
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117048] ivities, detailing the study  procedures and their timing 
(including tolerance limit s for timing).
Appendix [ADDRESS_117049] to minor 
alterati ons; however, the actual time must be recorded correctly in the eCRF.  Failure or delays 
(i.e., outsi de st ipulated time allowances) in performing procedures or o btaining samples, 
including those due to legit imate clinical issues (e .g., equi pment technical problems, venous 
access difficult y, or subject default ing or turning up late on an agreed scheduled procedure) must
be docum ented in writ ing via a file note but will not be considered as a protocol deviat ion
.
Unless otherwise stated in subsect ions below, all s amples collected for specified laboratory  tests 
will be destroy ed wi thin [ADDRESS_117050]’s
preexist ing condit ions, including clinically significant signs and symptoms of the disease under 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117051] any  change in the condit ion(s) 
and the occurrence and nature of any AEs.  
The invest igator will interpret and document whether or not anAE has a reasonab lepossib ility 
of being related to study treatment , or a study procedure, taking into account t he disease, 
concomitant treatment or pathologies.  
A “reasonable possibilit y”means that there is a potenti al cause and effect relat ionship between 
the IP, and/or study  procedure and the AE .
Planned surgeries should not be reported as AEs unless the underlying medical condit ion has 
worsened during the course of the study .
If a subject’s IP is discont inued as a result of an AE, study  site personnel  must report thi s to Lilly 
or its desi gnee via eCRF .
9.2.1. Serious Adverse Events
An SAE is any  AE from this stu dy that resul ts in one of the fo llowing:
death
initial or prolonged inpatient hospi[INVESTIGATOR_3094]
a life- threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
congenital ano maly/birth defect
important medical events that may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_313] m ay jeopardi zethe subject or may requi re interventi on to prevent 
one of the other outcomes listed in the definit ion above.
when a condit ion related to the PFS necessitates medical or surgical intervention to 
precl ude ei ther perm anent impairment of a body  function or permanent damage to a body  
structure, the seri ous outcom e of “requi red intervent ion” will be assigned.
Study  site personnel  must al ert the Lilly  CRP/CP, or i ts desi gnee, of  any SAE as soon as 
pract ically possible.
Addit ionally , study site personnel  must al ert Lilly Global Patient Safet y,or its desi gnee ,of any 
SAE wi thin [ADDRESS_117052] 
discontinued from and/or com pleted the study  (the patientsummary eCRF has been completed).  
However, if the invest igator learns of any SAE, including a death, at any time after a subject has 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 35
LY3298176been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  parti cipat ion, the invest igator m ust prom ptly notify Lilly . 
Pregnancy (maternal or paternal exposure to IP) does not meet the definit ion of an adverse event.  
However, to fulfill regulatory  requi rements any  pregnancy  should be reported following the SAE 
process t o collect data on the outcome for both mother and fetus.
[IP_ADDRESS]. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse react ions (S[LOCATION_003]Rs) are serious events that are not listed 
in the IB and that the investigator reports as related t o IPor procedure .  Lilly  has procedures that 
will be fo llowed f or the recording and expedited reporting of S[LOCATION_003]Rs that are consistent with 
global regulat ions and the associated detailed guidances.
9.2.2. Adverse Events of Special Interest
[IP_ADDRESS]. Hypoglycemia
Tirzepati de is an incretin which acts on the pancreatic β cell as a non -secretagogue; therefore, the 
risk of hypoglycemia is very low.
If hypoglycemia occurs, each epi[INVESTIGATOR_105396] o f care by  [CONTACT_105417]’s 
discreti on. As a general safet y precaut ion, subjects will be trained during the baseline period 
about si gns and symptom s of hypoglycemia, how to treat hy poglycemia, and how to collect 
appropriate informat ion for each epi[INVESTIGATOR_51943].
Hypoglycemia may  be identified by [CONTACT_105418] 
(whether confirmed or unconfirmed by [CONTACT_105419]) or by  [CONTACT_41225]/plasma glucose 
samples co llected during study visits.
Subjects with T2DM willbe given gluco meters (plus consumables such as test strips, lancets , 
alcoho l swabs etc)by [CONTACT_105420].  Subjects receiving glucometers will record relevant informat ion (for 
example, glucose values, symptoms) in a site developed diary.Subjects without T2DM may , at 
the invest igator’s discretion, be given gluco meters to assist in the evaluation o f reported 
symptoms consistent with hypoglycemia.  Subjects receiving gluco meters will record relevant 
inform ation (for example, glucose values, symptoms) in a diary .
Invest igators should use the fo llowing definit ions and criteria when diagnosing and categorizing 
an epi[INVESTIGATOR_105397] (the PG values in this sect ion refer to values 
determined by a laboratory  or Interna tional Federati on of  Clinical  Chemistry  and Laboratory  
Medicine plasma -equivalent glucose meters and strips) (American Diabetes Associat ion 2019) :
Glucose Alert Value (Level 1):
Documented symptomatic hypoglycemia is defined as any time a subject feels 
that he or she is experiencing symptoms and/or signs associated with 
hypoglycemia, and has a PG level of ≤70 mg/dL (≤3.9 mmo l/L).
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 36
LY3298176Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by t ypi[INVESTIGATOR_105398], but with a measured PG 
≤70mg/dL ( ≤3.9 mmo l/L).
Documented unspecified hypoglycemia is defined as any event with no 
inform ation about symptoms of hypoglycemia available, but with a measured PG 
≤70 m g/dL (≤3.9 mmo l/L).
Clinically Significant Hypoglycemia (Level 2):
Documented symptomatic hypoglycemia is defined as any time a subject feels 
that he/she is experiencing symptoms and/or signs associated with hypoglycemia, 
and has a PG level of <54 m g/dL (<3.0 mmo l/L).
Documented asymptomatic hypoglycemia is defined as any event not 
accompanied by t ypi[INVESTIGATOR_10921], but with a measured PG 
<54mg/dL (<3.0 mmo l/L).
Documented unspecified hypoglycemia is defined as any  event wi th no 
inform ation about symptoms of hypoglycemia available, but with a measured PG 
<54 m g/dL (<3.0 mmo l/L).
Severe Hypoglycemia (Level 3):
Severe hypoglycemia is defined as an epi[INVESTIGATOR_105399], 
glucagon, or other resuscitative act ions.  These epi[INVESTIGATOR_105400].  Blood glucose 
measurements may  not be available during such an event, but neurological 
recovery  attributable to the restoration of BG to normal is considered sufficient 
evidence that the event was induced by a low BG concentration.  
Other Hypoglycemia Categories:
Nocturnal hypoglycemia is defined as any hypo glycemic event that occurs 
between bedt ime and waking.
If a hypoglycemic event meets the criteria of severe, the invest igator must record the event as 
serious on the AE pages of the eCRF and reported to Lilly as an SAE.
To avoid duplicate reporting, all co nsecutive plasma glucose values ≤70 mg/dL (3.9 mmo l/L) 
occurring within a 1 -hour period may be considered to be a single hypoglycemic event (Weinberg 
et al. 2010; Danne et al. 2013).
In each case of suspected or confirmed hypoglycemia, it is important that the event be properly  
categori zed, the effect of the intervention be assessed, and the frequency of hypoglycemia be 
evaluated.  The role of dietary  changes and physical  exercise (or any  other contribut ing factor) in 
the development of an event should be e stablished.  The subject should receive addit ional 
education, if deemed appropriate.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117053] in all studies with tirzepatide including this 
study .  Acute pancreat itisis an acute inflammatory process of the pancreas that may also invo lve 
peripancreat ic tissues and/or remote organ sy stems (Banks and Freeman 2006).  The diagnosis of 
acute pancreatit is requires 2 of the fo llowing 3 features:
abdo minal pain, characterist icof acute pancreat itis (generally located in the 
epi[INVESTIGATOR_82347] [Banks and 
Freeman 2006; Ko izumi et al . 2006]; the pain is often associated with nausea 
andvomiting);
serum  amylase (total and/or pancrea tic) and/or lipase ≥3× ULN
characterist ic findings of acute pancreat itis on computed tomography  (CT) scan or 
magnet ic resonance imaging (MRI).
If acute pancreat itis is suspected, appropriate laboratory  tests (including levels of pancreat ic 
amylase and lip ase) shoul d be obtained via the local laboratory .  Imaging studi es, such as 
abdo minal CT scan with or without contrast, MRI, or gallbladder ultrasound, should be 
perform ed.  If laboratory  values and/or abdominal imaging support the diagnosis of acute 
pancr eatitis, the subject must discont inue IP, and will be discont inued fro m the study  after 
completing all E Dand fo llow-up procedures.  The most appropriate diabetes therapeutic regimen 
will be decided by [CONTACT_3170], based on the subject’s clinical stat us.  A review of the 
subject’s medical data, including conco mitant m edicat ions, shoul d be conducted to assess 
potenti al causes of pancreat itis.
Each case o f AE of pancreat itis must be reported.  If t ypi[INVESTIGATOR_10926]/or symptoms o f 
pancreat itis are present and confirmed by [CONTACT_11018] (lipase or amylase [total and/or 
pancreat ic]) and imaging studies, the event must be reported as an SAE.  For a potential case that 
does not m eet all of these criteria, it is up to the investigator to determine the seriou sness of the 
case (AE or SAE) and the relatedness o f the event to IP.
Each subject will have measurements of amylase and lipase, part of safet y laboratory  tests as 
shown in Section 2(Schedule of Act ivities)to assess the effects of study  treatment on pancreat ic 
enzyme levels.  Serial measures of pancreat ic enzymes have limit ed clinical value for predict ing 
epi[INVESTIGATOR_105401] s (Nauck et al. 2017; Steinberg et al. 
2017a; Steinberg et al. 2017b).  Thus, further diagnostic fo llow-up of  cases of asymptom atic 
pancreat ic hyperenzymemia (lipase and/or pancreatic amylase ≥3×ULN) is not mandated but 
may be performed based o n the invest igator’s clinical judgment and assessment of the subject ’s 
overall clinical condit ion.  If further diagnostic assessment due to asymptomat ic 
hyperenzymemia will be warranted, it should fo llow Lilly  standard al gorithm for the m onitoring 
of pancr eatic enzymes (refer to Appendix 6 ).
[IP_ADDRESS]. Thyroid Malignancies and C -Cell Hyperplasia
Individuals with personal or family history  of MTC and/or MEN 2 will be excluded from the 
study , as well  as thos e with calcitonin ≥20 pg/m L at screening.  Subjects who are diagnosed with 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 38
LY3298176MTC and/or MEN -[ADDRESS_117054].
[IP_ADDRESS]. Supraventricular Arrhythmias and Cardiac Conduction Disorders
Treatment -emergent cardiac conduction disorders shoul dbe further evaluated.  Subjects who 
develop any event from this group of di sorders shoul d undergo an ECG. Addit ional diagnostic 
tests to determine exact diagnosis should be performed, as needed. The specific diagnosis will 
berecorded as an AE in the eCRF . Events that meet criteria for serious conditions as described 
in Section 9.2.1 (Seri ous Adverse Events) must be reported as SAEs .
[IP_ADDRESS]. Hypersensitivity Events
Many  drugs, but parti cularly bio logic agents, carry the risk of systemic hypersensit ivity 
reacti ons. If such a react ion occurs, additional data describing each symptom should be provided 
to the sponsor in the eCRF. 
Sites shoul d have appropri ately  trained medical  staff and appropri ate medical equipment 
available when study  subjects are receiving stu dy drug. It is recommended that subjects who 
experience a systemic hypersensit ivity react ion be treated per the local standard of care.
In the case of generalized urticaria or anaphylaxis, addit ional blood sam ples shoul d be co llected 
as described in Sect ion 9.6.3 (Immunogenicit y Assessments).  Laboratory  resul ts are provi ded to 
the sponsor via the central or a referral laboratory .
[IP_ADDRESS]. Injection-S ite Reactions
Inject ion-site assessments for l ocal tolerabilit y will be conducted, when reported as:
an AE fro m a subject, or
a clinical observat ion from an invest igator.
Reported inject ion-site reacti ons will  be characterize d within the fo llowing categori es:
edem a
erythema
induration
itching
pain
Inject ion-site reacti ons will  be collected on the eCRF created for these events.  At the time of AE 
occurrence, unscheduled samples may be collected for measurement of tirzepat ide ADA and 
tirzepat ide PKif the event is suspected to be immune related by  [CONTACT_3170] .
All injecti on-site reacti ons reported as AEs will be closely monitored until reso lution.  The report 
of a clinically  significant AE of inject ion-site reacti on may prom pt notificati on of  the sponsor, 
clinical photography , and referral  for derm atologic evaluat ion and consideration of a skin biopsy 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 39
LY3298176and laboratory  evaluat ions (ALT, AST, complete blood coun t with percent eosinophils, and 
additional immunogenici ty testing).
Site staff will be provided wit h separate instructions/training on how to evaluate inject ion-site 
reacti ons and thei r severi ty in a consistent manner.  Photographs of inject ion-site reacti ons m ay 
be taken if deemed necessary by [CONTACT_105421] -keepi[INVESTIGATOR_105402]; however, the photographs will not be used to evaluate the severit y of injecti on-site 
reacti on.
[IP_ADDRESS]. Hepatobiliary Disorders
All events of treatm ent-emergent biliary co lic, cholecyst itis, or other suspected events related to 
gallbladder disease should be evaluated and addit ional diagnostic tests performed, as needed. In 
cases o f elevated liver m arkers, hepatic m onitoring shoul d be ini tiated as outlined in 
Secti on9.4.10.1 (Hepatic Safet y) and Appendix 4 .
[IP_ADDRESS]. Severe Gastrointestinal Adverse Events
Tirzepati de m ay cause severe GI AEs, such as nausea, vo miting, and diarrhea.  Informat ion 
about severe GI A Es as well as antiemetic/antidiarrheal use will be collected in the AE form of 
the eCRF.
[IP_ADDRESS]. Acute Renal Events
Renal safety  will be assessed based on routine laboratory renal  functional assessment as well as 
assessment of AEs suggest ive o f acute renal failure or worsening of chronic renal failure .  
Subjects with GI AEs, including nausea, diarrhea, and vo miting are at increased risk of 
developi[INVESTIGATOR_105403].  Dehydrat ion may cause a deterioration in renal func tion, including 
acute renal failure.  Subjects should be advised to notify invest igators in case of severe nausea, 
frequent vomit ing, or symptoms of dehydrat ion.
9.2.3. Complaint Handling
Lilly co llects product complaints on IPsand drug delivery  systems used in clinical trials in order 
to ensure the safet y of study  partici pants, m onitor quali ty, and to facilitate process and product 
improvements.
Subjects shoul d be instructed to contact [CONTACT_105422] i f he or she has a 
complaint or probl em wi th the IPor PFS so that the situation can be assessed.
9.3. Treatment of Overdose
For the purposes of this study , an overdose of tirzepati deis considered any dose higher than the 
protocol -specified dose .  There is no specific ant idote.  The subject should be watched for GI 
symptoms and hypoglycemia.  Treatment is supportive, depending on the subject ’s symptoms.  
For detailed informat ion,refer to the IB for tirzepati de.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117055] , laboratory  testsdetailed in Appendix 2 shoul d be conducted accordi ng to the 
Schedule of Activities (Secti on2).
Any clinically  significant findings from lab oratory tests that resul t in a di agnosis and that occur 
after the subject receives the first dose of the IP should be reported to Lilly , or i ts designee, as an 
AE via eCRF.
9.4.2. Vital Signs
For each subject , vital signs measurements should be conducted according to the Schedule of 
Activities (Secti on 2).  
Blood pressure and pulse rate should be measured after at least 5minutes in the supi[INVESTIGATOR_2547].
Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of diz ziness or 
posture -induced symptoms.  Addit ional vital signs may be m easured during each study  period if 
warranted
.
9.4.3. Body Weight and Waist Circumference
Weight and waist circumference will be measured according to the schedule provided in the 
Schedule of Act ivities (Section 2).  
Subjects will be weighed at approximately the same time in the morning, before dosing and after 
an overnight fast and evacuat ion of the bowel and bladder, if possible.  Weight will be measured 
twice on each scheduled occasio n, wi th the subject steppi[INVESTIGATOR_105404].  
A thi rd measurement will be made if the first 2 measurements are >0.[ADDRESS_117056] , a single 12 -lead ECG shoul d be collected according to the Schedule of 
Activities(Secti on 2). 
Electrocardiograms must be recorded before collecting any blood samples.
  Subjects must be 
supi[INVESTIGATOR_17044]  [ADDRESS_117057] ion and remain supi[INVESTIGATOR_105405] 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e [ADDRESS_117058] i gat or (a p h ysicia n or q ualifie d 
desi g nee) at t he site as s o o n after t he ti me of E C G c ollect i o n as p ossi ble, a n d i deall y w hile t he 
s u bject is st ill prese nt, t o deter mi ne w het her t he s u bject meets e ntr y criteria at t he rele va nt 
visit(s) a n d f or i m me diate s u bject ma na ge me nt, s h o ul d a n y cli nicall y rele va nt fi n di n gs be 
i de nt ifie d.  
If a cli nicall y si g nifica nt fi n di n g is i de nt ifie d (i ncl u di n g, b ut n ot li mite d t o, c ha n ges i n Q T/ Q Tc 
i nt er val  f r o m  b aseli ne) after e nr oll me nt, t he i n vesti gat or will deter mi ne if t he s u bject ca n 
c o nti n ue i n t he st u d y .  T he i n vest i gat or, or q ualifie d desi g nee, is res p o nsi ble f or deter mi ni n g if 
a n y c ha n ge i n s u bject ma na ge me nt is nee de d a n d m ust d oc u me nt his/ her re vie w of t he E C G 
pri nte d at t he ti me of c o llect i o n.  A n y ne w cli nicall y  rele va nt fi n di n g s h o ul d be re p orte d as a n 
a d verse e ve nt .A n y cli nicall y si g nifica nt fi n di n gs fr o m E C Gs t hat res ult i n a dia g n osis a n d t hat 
occ ur after t he s u bject recei ves t he first d ose of t he I P, s h o ul d be re p orte d t o Lill y ,or i ts 
desi g n ee ,as a n A E via e C R F. 
9. 4. 6. P h y si c al E x a mi n ati o n s 
P h ysical e xa mi nat i o ns a n d r o uti ne me dical assess me nts will be c o n d ucte d as s pecifie d i n 
Secti o n 2( Sc he d ule of Act i vit ie s) a n d as cli nicall y i n dicate d. 
9. 4. 7. 6- p oi nt Pl a s m a Gl u c o s e Pr ofil e 
Pl as ma s a m ples will be ta ke n f or t he pr ofili n g of plas ma gl uc ose bef or e a n d after m eals, as 
s pecifie d i n Secti o n 2.  A n y plas ma gl uc ose res ults t hat f ulfil t he criteria of h y p o gl yce mia will be 
ca pt ure d i n t he eC R F as s pecifie d i n Sect i o n 9. 2. 2. [ADDRESS_117059] a s m a Gl u c o s e ( S M P G) 
S u bjects wi t h  T [ADDRESS_117060] e x perie nces s y m pt o ms of h y p o gl yce mia as s pecifie d C CI 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117061] ivities (Section 2).  Results of the SMPG need not be databased, but 
investigator review of glucose results clinically indicat ive of hypoglycemia or symptomat ic 
hyperglycemia is required.
All hypoglycemic events will be captured in the e CRF as specified in Section [IP_ADDRESS] .  Clinically 
significant hyperglycemic e vents shoul d be reported as AEs. 
9.4.9. Suicidal Ideation Assessment
Overweight and obese subjects are at an increased risk of depression (Luppi[INVESTIGATOR_105406]. 2010).  
Depressio n can increase the risk of suicidal ideat ion and behavior.  Therefore, study  subjects will 
be screened at trial entry  for depressi on, suicidal  ideati on and behavi or using the C -SSRS an d 
PHQ -9 as specified in the Schedule o f Activities (Secti on 2), and excluded fro m the study  if they  
meet thresho lds defined by [CONTACT_105423] [ 35] and [3 6].
The C
-SSRS (Columbia Lighthouse Project [WWW]) is a scale that captures the occurrence, 
severit y, and frequency  of suicidal ideation and/or behavior during the assessment period.  The 
scale includes suggested questions to solicit the type of informat ion needed to determine if 
suicidal ideation and/or behavior occurred.  The tool was developed by  [CONTACT_105424] a counterpart to the Columbia Classification 
Algori thm of Suicide Assessm ent categori zation of sui cidal  events.  For this study , the C -SSRS 
is adapted for the assessment of the ideat ion and behavior categories only.  The Intensit y of 
Ideati on and Lethalit y of Behavi or secti ons are rem oved.
The PHQ -[ADDRESS_117062] ical Manual -
IV depression criteria as “0” (not at all) to “3” (nearly  every day ), was devel oped f or use in 
primary  care settings (Kroenke et al. 2001).
9.4.10. Safety Monitoring
The Lilly clinical pharmaco logist or CRP /scientist will mo nitor safety  data throughout the course 
of the study .
Lilly will review SAEs wit hin time frames mandated by [CONTACT_17069].  The Lilly clinical 
pharmaco logist or CRP will periodically  review the following data:
trends in safety  data
laboratory  analy tes including glucose, amylase, and lipase
serious and nonserious AEs, including AEs of interest (see Section 9.2.[ADDRESS_117063] ) 
When appropriate, the Lilly clinical pharmaco logist or CRP will consult wit h the funct ionally 
independent Global Pat ient Safety  therapeut ic area physician or clinical research scient ist.
[IP_ADDRESS]. Hepatic Safety
Close hepat ic monitoring
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 43
LY3298176Laboratory  tests ( Appendix 4 ), including ALT, AST, ALP, TBL, direct bilirubin, 
gamma- glutamyl  transferase (GGT), and creatine kinase (CK), should be repeated within 48 to 
72 hours to confirm the abnormalit y and to determi ne if i t is increasing or decreasing, if 1 or 
more of these condit ions occur:
If a participant with baseline results of ... develops the following elevations:
ALT or AST <1.5 ×upper limit of normal (ULN) ALT or AST ≥3×ULN
ALP <1.5 ×ULN ALP ≥2×ULN
TBL <1.5×ULN TBL ≥2×ULN (except for subjects with Gilbert’s syndrome)
ALT or AST ≥1.5×ULN ALT or AST ≥2×baseline
ALP ≥1.5×ULN ALP ≥2×baseline
TBL ≥1.5×ULNTBL ≥2×baseline (except for subjects with Gilbert’s 
syndrome)
If the abnormalit y persists or worsens, clinical and laboratory  monitoring, and evaluat ion for 
possible causes of abnormal liver tests should be init iated by  [CONTACT_17070] -designated CP/CRP.  At a minimum, this evaluat ion shoul d include physical 
examinat ion and a thorough medical history , including symptom s, recent illnesses (for example, 
heart failure, systemic infect ion, hypotension, or seizures), recent travel, history  of concomi tant 
medicat ions (including over -the-counter), herbal and dietary  supplements, history  of alcoho l 
drinking and other substance abuse.
Initially, m onitoring of  symptoms and hepat ic biochemical tests should be done at a frequency o f 
1 to 3 times weekly , based on the parti cipant’s clinical condit ion and hepat ic biochemical tes ts.  
Subsequently, the frequency  of monitoring m ay be l owered to once every  1 to 2 weeks, if the 
participant’s clinical condit ion and l ab results stabilize.  Moni toring of ALT, AST, ALP, and 
TBL should cont inue unt il levels normalize or return to approxima te baseline levels.
Com prehensive hepatic evaluation  
A co mprehensive evaluat ion shoul d be perform ed to search for possible causes of liver injury  if 
one or m ore of these condit ions occur:
If a participant with baseline results of...  develops the follow ing elevations:
ALT or AST <1.5 ×ULN ALT or AST ≥3×ULN with hepatic signs/symptoms*, or
ALT or AST ≥5×ULN
ALP <1.5 ×ULN ALP ≥3×ULN
TBL <1.5× ULN TBL ≥2×ULN (except for subjects with Gilbert’s syndrome)
ALT or AST ≥1.5×ULN ALT or AST ≥2×baseline with hepatic signs/symptoms*, or
ALT or AST ≥3×baseline
ALP ≥1.5×ULN ALP ≥2×baseline
TBL ≥1.5×ULN TBL ≥1.5×baseline (except for subjects with Gilbert’s syndrome) 
* Hepatic signs/symptoms are severe fatigue, nausea, vomiting, right upper quadrant abdominal pain, fever, rash, and/or 
eosinophilia >5%.
At a minimum, this evaluat ion should include physical examinat ion and a thorough medical 
history , as outlined above, as well as tests for prothrombin t ime-internat ional normalized rat io 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 44
LY3298176(PT-INR); tests for viral hepat itis A, B, C, or E; tests for autoimmune hepat itis; and an 
abdo minal imaging study (for example, ultrasound or CT scan).  
Based on the subject’s history  and initial resul ts, further testing should be considered in 
consultation wit h the Lilly -designated m edical m onitor, including tests for hepatit is D virus 
(HDV), cy tomegalovirus (CMV), Epstein -Barr vi rus (EBV), acetaminophen levels, 
acetaminophen protein add ucts, uri ne toxi cology screen, Wilso n’s disease, blood alcoho l levels, 
urinary  ethyl  glucuronide, and serum phosphat idylethano l.  Based on the circumstances and the 
investigator’s assessment of the participant’s clinical condit ion, the investigator should consider 
referring the participant for a hepatologist or gastroenterologist consultation, magnet ic resonance 
cholangiopancreatography  (MRCP), endoscopi c retrograde cholangiopancreatography  (ERCP), 
cardi ac echocardi ogram , or a liver biopsy.  
Addit ional safety data collect ion in hepat ic safet y eCRF shoul d be perform ed in study  
participants who meet 1 or more of the fo llowing condi tions: 
Elevat ion of serum ALT to ≥5× ULN on 2 or more consecutive blood tests (if baseline 
ALT <1.5 × ULN)
oIn parti cipants wi th baseline ALT ≥1.5 × ULN, the thresho ld is ALT 
≥3×baseline on 2 or more consecut ive tests
Elevated serum TBL to ≥2× ULN (except for cases of known Gilbert’s syndro me)
oIn parti cipants wi th baseline TBL ≥1.5× ULN, the thresho ld should be TBL 
≥2×baseline
Elevat ion of serum ALP to ≥2× ULN on 2 or more consecutive blood tests 
oIn parti cipants wi th baseline ALP ≥1.5 × ULN, the thresho ld is ALP ≥2× baseline 
on 2 or more consecutive blood tests
Hepati c event consi dered to be a SAE
Discontinuati on of  study  drug due to a hepatic event
Note: the interval between the [ADDRESS_117064] ivities(Secti on 2),venous blood samples 
of approximately  
3mL each will be co llected to determine the plasma concentrations o f 
tirzepat ide.  A maximum o f [ADDRESS_117065] ion and handling of blood samples will be provided by [CONTACT_456].  
The actual  date and time (24 -hour clock time) of each sampling will be recorded.
Failure or being late (i .e., outside stipulated time allowances) to perform obtain samples due to 
legitimate clinical issues (e .g., equi pment technical problems, venous access difficult y, or subject 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 45
LY3298176defaul ting or turning up late on an agreed scheduled procedure) will not be considered as 
protocol  deviat ions but the CRU will have to notify the sponsor in writ ing via a file note.
9.5.1. Bioanalysis
Samples will  be analyzed at a l aboratory  approved by  [CONTACT_17077] a facilit y 
designated by  [CONTACT_456] .
Concentrations of tirzepat ideand acetaminophen will be assayed using a validated liquid 
chromatography  tandem mass spectrom etrymethod.  
Bioanaly tical samples collected to m easure IPconcentrations will be retained for a maximum o f 
[ADDRESS_117066] oratory  analyses such as metab olism,protein binding, or 
bioanalyt ical method cross -validation .
9.6. Pharmacodynamic s
9.6.1. Gastric Emptying
Acetaminophen is a well -established marker for the rate and extent of gastric empt ying. It is 
rapi[INVESTIGATOR_105407]. A delay in gastric 
emptying is reflected in the alterations to the concentration -time profile of acetaminophen , 
specifically, decreasing its C maxand tmaxwithout altering the extent (total drug amount) of 
absorpti on. A dose of approximately [ADDRESS_117067] and 
sixth tirzepati de doses ( Schedule of Activit ies [Secti on 2]). 
Venous blood samples of approximately 2 mL each will be co llected to determine the plasma
concentrations of acetaminophen (Schedule of Activit ies [Section 2]).  Up to [ADDRESS_117068] ion 2(Schedule of 
Activities).  Refer to Section 9.4.[ADDRESS_117069] according to the Schedule of Activit ies (Section 2), to determine ant ibody  
producti on against ti rzepat ide.  Up to 3 a dditional samples may  be collected if there is a 
possibilit y that an AE is immuno logically mediated (see Section [IP_ADDRESS] ).  All samples for 
immunogenicit y testing shoul d have a time -matched sample for PK analysis where relevant.  
Detailed instructions for the sam ple collect ions and handling will be provided by [CONTACT_941] s ponsor.  
The actual  date and [ADDRESS_117070] anti drug ant ibodies 
(ADA) in the presence of t irzepati de at a l aboratory
 approved by  [CONTACT_456].  Ant ibodies may 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117071] 
native GIP and/or GLP -1. 
All subjects will have an ADA sample measured at early discont inuat ion or at Day 64± 1 day .  
A risk -based approach will be used to monitor subjects who develop treatment -emergent ADA 
(TE ADA), defined in Sect ion 10.3.4 (Evaluat ion of Immunogenicit y). 
Clinically significant TE ADA will be defined as any TE ADA at the last visit with: 
a high ti ter (≥1280) or an increasing titer from last measured value 
an associ ation with a moderate -to-severe inject ion-site reacti on 
Subjects who have clinically signif icant TE ADA at early  disconti nuation or at the safety  
follow-up shoul d be f ollowed wi th ADA testing every  [ADDRESS_117072] 
returned to the baseline ADA titer (defined as ADA titer within 2 -fold of baseline) or for up to 
1year, whichever is less. A PK sample may be collected at the fo llow-up immunogenicit y 
assessment(s), if warranted and agreed upon by  [CONTACT_105425]. 
Every  effort shoul d be made to contact [CONTACT_105426] -up immunogenicit y assessment; 
however, if su bjects are unwilling or unable to return for the visit, this is not considered a 
protocol  deviat ion. 
Subjects followed for at least [ADDRESS_117073] visit, or for a shorter 
period if local  regulat ions and ERBs allow , at a f acility selected by  [CONTACT_456].  The durati on 
allows the sponsor to respond to future regulatory  requests related to the tirzepat ide.  Any 
samples remaining after 15 y ears will be destroyed.
9.7. Genetics
A blood sam ple will be collected for pharmacogenetic analysis as specified in the Schedule of 
Activities(Secti on 2), where local regulat ions allo w.  
Samples willnotbeused to conduct unspecified disease or populat ion genet ic research either 
now or in the future.  Samples will be used to investigate variable exposure or response to 
tirzepat ideand to i nvest igate genet ic variants thought to play a role in T2DM .  Assessment of 
variable response may include evaluation of AEs or differences in efficacy .  
All samples will be coded w ith the subject number.  These samples and any  data generated can 
be linked back to the subject only by [CONTACT_47550] .  
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117074] visit, or for a shorter 
period if local regulat ionsand/or ERBs impose shorter time limits , for the study  at a f acilit y 
selected by [CONTACT_47551] i ts desi gnee .  This retenti on peri od enables use of new techno logies, response 
to regulatory  quest ions, and invest igation of variable response that may  not be observed unt il 
later in the devel opment of tirzepat ideor after tirzepati deis co mmercially available.  
Molecular techno logies are expected to improve during the [ADDRESS_117075] ore the effects of tirzepat ide on m eal intake and appeti te sensat ion, subjects will be asked 
to rate their appetite sensat ions using a 100- mm visual analog scale (VAS) for parameters of 
hunger, fullness, sat iety, and prospective food consumpt ion prior to dosing on Day  1, and in the 
fasted state while inpatient as well as on scheduled outpatient visits.  These measurements shall 
be perform ed according to the Schedule of Act ivities (Secti on 2).
The VAS is a validated tool to assess appetite sensation parameters (Flint et al. 2000).  The VAS 
is presented as a 10 -cm (100 -mm) line, anchored by [CONTACT_105427], usually  “extrem ely” and 
“not at all”.  Subjects are required to rate their subjective sensat ions on four 100
-mm scales 
combined wit h questions similar to the fo llowing:
1.“How hungry  do y ou feel?”
2.“How satisfied do y ou feel?”
3.“How ful l do y ou feel?”
4.“How m uch do y ou think y ou coul d eat?”
A staff member will use a caliper to measure the distance fro m [ADDRESS_117076] the measurement in the source document.  Overall appet ite score 
is calculated as the average of the 4 individual scores: satiet y + fullness + (100 -prospective food 
consumption) + (100- hunger) / 4 (van Can et al. 2014).  The higher overall appet ite score 
indicates less appet ite, and the lower score indicates more appetite.
9.10. Health Eco nomics
Thissection is not applicable for this study.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117077] variabilit y (coefficient of variat ion [CV]) 
was est imated to be 15.7% and 21.9%, respectively (derived fro m study  I8F-MC-GPGA ). Based 
on this assumpt ion, 24subjects will provide a precisio n of 0.09 and 0.13 on a l og-scale for AUC 
and C max, respectively. This would resul t in a 90% probabilit y that the half -width of the 90% 
confidence interval (CI) of the ratio of the geometric least square means for AUC and C maxis no 
larger than 8.8% and 12.0%, respectively .
10.2. Populations for Analyses
10.2.1. Study Participant Disposition
A detailed description o f subject disposit ion will be provided at the end of the study . All 
subjects who discontinue from the study  will be identified, and the extent of their participation in 
the study  will be reported.  If known, a reason for their discont inuation will be given.
10.2.2. Study Participant Characteristics
The subject’s age, sex, weight, height, BMI, or other demographic characterist ics will be 
recorded and may be used in the PK and safet y analyses as quant itative of classificat ion 
variables.
10.3. Statisti cal Anal yses
Statistical analysis o f this study  will be the responsibilit y of Eli Lilly and Com pany  or its 
designee .
Pharmacokinet ic and PDanalyses will be conducted on data from all subjects who receiv eat 
least one dose of the IPand have evaluable data.  
Safety analyses will be conducted for all subjects who receive at least one dose of the IP, 
whether or not they  com pleted all protocol requirements .
Addit ional exploratory  analyses of the data will be conducted as deemed appropriate.  Study  
resul ts may be pool ed wi th the resul ts of other studies for populat ion PKanalysis purposes.   
10.3.1. Safety Analyses
[IP_ADDRESS]. Clinical Evaluation of Safety
All IP, protocol  procedure AEs , and com plaints will be listed, and if the frequency o f events 
allows, data will be summarized using descript ive methodol ogy.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117078] sui table term fro m themedical regulatory  dictionary.
The number of IP-related SAEs will be reported.
[IP_ADDRESS]. Statistical Evaluation of Safety
Safety param eters that will be assessed include safety  laboratory  parameters , vital signs, 
 TEAEs (including TEAEs of special interest), and SAEs .  The 
param eters will  be listed and summarized using standard descriptive statist ics.  Addit ional 
analysis will be performed if warranted upon review of the data. All AEs related to study  or
protocol  procedure will be listed, and if the frequency of events allows, will be also summarized 
using descript ive methodol ogy.
Hypoglycemic events, a s defined in Section [IP_ADDRESS] , will be summarized and listed .
Physical examinat ions and ECGs will be performed for safet y monitoring purposes and will not 
be presented.  If warranted, a dditional analy ses will  be perf ormed upon review of the data.
10.3.2. Pharmacokinetic Analyses
[IP_ADDRESS]. Pharmacokinetic Parameter Estimation
Pharmacokinet ic parameter estimates for tirzepat idewill be calculated by [CONTACT_105428]. The primary  param eters f or analysis will be C max, 
AUC 0-∞ ,AUC 0-tlast, and t max.  Other nonco mpartmental parameters, such as half-life, apparent 
clearance, and apparent volume of distribut ion may be reported.
[IP_ADDRESS]. Pharmacokinetic Statistical Inference
Planned PK parameters will be summarized with descript ive statistics.
10.3.3. Pharmacodynamic Analyses
[IP_ADDRESS]. Pharmacodynamic Parameter Estimation
Acetaminophen PK parameters will be est imated to assess the effect of tirzepat ide on gastric 
emptying delay .The PK parameter estimates for acetaminophen will be calculated by  [CONTACT_105428]. The primary  param eters f or analysis will be the C max, 
the AUC 0-tlast, and the tmaxof acetaminophen . Other parameters, such as half-life, apparent 
clearance, and apparent volume of distribut ion, may be reported.
A co mpar ison of acetaminophen parameters on Day  
-1 (pri or to study  drug) and fo llowing first 
and sixth dose of study  drug will be summarized.
[IP_ADDRESS]. Pharmacodynamic Statistical I nference
Pharmacokinet ic parameters will be evaluated to estimate the impact of tirzepat ide on gastric 
emptying and on the PK of acetaminophen .  Log -transformed C maxand AUC will be evaluated 
in a linear mixed- effects m odel, with day (-1, 2, 37) as a fixe d effect and subject as a random 

I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117079].  The differences in C max and AUC between acetaminophen + tirzepat ide (Test; Days 2 
and37) and acetaminophen alo ne (Reference; Day -1) will be back- transform ed to present the
ratios of  geom etric least squares means and the corresponding 90% CI.   Other parameters may be 
analyzed in this way  as needed.
The t maxwill be analyzed using a Wilcoxon signed rank test.  Estimates of the median difference 
based on the observed medians and 90% CIs from the Wilcoxon test w ill be calculated.
Planned PK parameters will also be summarized wit h descriptive statist ics.
Pharmacodynamic parameters that will be assessed include body  weight , appetite VAS scores 
and HbA1c .  The parameters will be listed and summarized using standard descript ive statistics.  
Addit ionalanalysis will be performed if warranted upon review of the data.
10.3.4. Evaluation of Immunogenicity
The frequency and percentage of subjects with preexist ing ADA and with TEADA +to 
tirzepat idewill be tabulated . Treatment -emergent ADAs are defined as those with a titer 2- fold 
(1 dilut ion) greater than the minimum required dilution if no ADAs were detected at baseline 
(treatment -induced ADA) or those with a 4 -fold (2 dilut ions) increase in t iter compared to 
baselin e if ADAs were detected at baseline (treatment -boosted ADA). The minimum required 
dilution of  the ADA assay  is 1:10. For the TE ADA+ subject s the distribution o f maximum t iters 
will be described.   If cross -reactivit y with native GLP -[ADDRESS_117080], CRP /investigator, or designee will consult with the 
appropriate medical director or designee to determine if it is necessary to amend the protocol.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 51
LY329817611. References
[ADA] American Diabetes Associat ion.  Glycemic targets.  Standards of medical care in 
diabetes-2019.  Di abetes Care.  2019;42(Suppl.  1):S61 -S70.
Banks PA, Freeman ML. Practice guidelines in acute pancreatit is.Am J Gastroenterol.   
2006;101(10):[ADDRESS_117081]. Col umbia -Suicide Severi ty Rating Scal e (C-SSRS) website. 
Available at: http://www.cssrs.columbia.edu . Accessed [ADDRESS_117082], Gimeno RE, D’ Alessio DA, 
Haupt A.  LY3298176, a novel dual GIP and GLP -[ADDRESS_117083] for the treatment of 
type2 diabetes m ellitus:  From  discovery  to clinical  proof  of concept.  Mol ecular m etabolism .  
2018;18:3 - 14.
Danne T, Philotheou A, Goldman D, Guo X, Pi[INVESTIGATOR_007] L, Cali A, Johnston P. A randomized trial
comparing the rate of hypoglycemia – assessed using continuous glucose monitoring – in
LY3298176 125 preschool children wit h type 1 di abetes treated wi th insulin glargine or NPH 
insulin (the PRESCHOOL study ). Pediatr Diabetes . 2013;14(8):[ADDRESS_117084] meal stud ies. Int J Obes . 2000; 
24(1):[ADDRESS_117085], in pat ients with type 2 di abetes: a randomized, placebo -controlled and active 
comparator -controlled phase 2 trial.  The Lancet.  2018;392([ZIP_CODE]):  2180- 2193.
Koizumi M, Takada T, Kawarada Y, Hirata K, Mayumi T, Yoshida M, Sekimoto M, Hirota M,
Kimura Y, [COMPANY_005] K, Isaji S, Otsuki M, Matsun o S; JPN. JPN Guidelines for the management
of acute pancreatit is: diagnostic criteria for acute pancreat itis. J Hepatobiliary Pancreat Surg.   
2006;13(1):25 -32.
Kroenke K, Spi[INVESTIGATOR_4280], Williams JB. The PHQ -9: validit y of a brief depressio n severit y 
measure. J Gen Intern Med . 2001;16(9):606 -613.
Luppi[INVESTIGATOR_4276], de Wit LM, Bouvy  PF, Stijnen T, Cuijpers P, Penninx BW, Zit man FG. 
Overweight, obesit y, and depressio n: a systemat ic review and meta -analysis of lo ngitudinal 
studi es. Arch Gen Psychiatry. 2010;67(3):[ADDRESS_117086] dulaglut ide.Diabetes Care . 2017;40(5):647 -
654.
Steinberg WM, Buse JB, Ghorbani MLM, Ørsted DD, Nauck MA; LEADER Steering 
Committee; LEADER Tri al Invest igators. Amylase, lipase, and acute pancreat itis in people 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 52
LY3298176with type 2 diabetes treated with liraglut ide: result s from the LEADER Rando mized Trial. 
Diabetes Care. 2017a;40(7):[ADDRESS_117087] of 
liraglutide on amylase, lipase, and acute pancreat itis in part icipants wi th overwei ght/obesi ty 
and normoglycemia, prediabetes, or ty pe 2 di abetes: secondary  analyses of pool ed data from 
the SCALE clinical development program. Diabetes Care. 2017b;40(7):839 -848.
van Can J, Sloth B, Jensen CB, Flint A, Blaak EE, Saris WH. Effects of the once -daily  GLP -1 
analog liraglut ide on gastric empt ying, gl ycemic parameters, appetite and energy  metabo lism 
in obese, non -diabet ic adults. Int J Obes (Lond) . 2014;38(6):784 -793.
Weinberg ME, Bacchetti P, Rushakoff RJ. Frequent ly repeated glucose measurements
overestimate the incidence of inpatient hy poglycemia and severe hyperglycemia. J Diabetes
Sci Technol . 2010;4(3):577 -582.
Young A. Inhibit ion of gastri c em ptying. Adv Pharmacol . 2005;52:99-121.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 53
LY329817612. Appendices
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 54
LY3298176Appendix 1. Abbreviations and Definitions
Term Definition
ADA antidrug antibodies
AE adverse event:  Any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), sympt om, o r disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.
ALP alkaline phosphatase
ALT alkaline phosphatase
AST aspartate aminotransferase
AUC area under the concentration versus time curve
AUC 0-∞ area under the concentration versus time curve from time zero to infinity
AUC 0-tlast area under the concentration versus time curve from time zero to time t, where t is the last 
time point with a measurable concentration
BMI body mass index
CI confidence interval
Cmax maximum observed drug concentration
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, or 
performance of a drug or drug delivery system.
compliance Adherence to all the study -related requirements, good clinical practice (GCP) requirements, 
and the applicable regulatory requirements.
confirm ation A process used to confirm that laboratory test results meet the quality requirements defined 
by [CONTACT_57994].  
Confirmation will either occur immediately after initial testin g or will require that samples 
be held to be retested at some defined time point, depending on the steps required to obtain 
confirmed results.
CP Clinical Pharmacologist
CRP Clinical Research Physician :  Individual responsible for the medical conduct of the study.  
Responsibilities of the CRP may be performed by a physician, clinical research scientist, 
global safety physician or other medical officer.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117088]
FSH follicle -stimulating hormone
GCP good clinical practice
GE gastric emptying
GI gastrointestinal
GIP glucose -dependent insulinotropic peptide
GLP-1 glucagon -like peptide 1
HCV hepat itis C virus
HIV human immunodeficiency virus
IB Investigator’s Brochure
ICF informed consent form
ICH International Co uncil forHarmonization
informed consent A process by [CONTACT_9444] a subject voluntarily confirms his or her willingness to participate in a 
particular study , after having been informed of all aspects of the study that are relevant to 
the subject ’sdecision to participate.  Informed consent is documente d by [CONTACT_3553] a 
written, signed and dated informed consent form.  
Investigational 
product (IP)Apharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical study , including products already on the market when used or assembled 
(formulated or packaged) in a way different from the authorized form, or marketed products 
used for an unauthorized indication, or marketed products used to gain further information 
about the authorized form.
investigator A person respo nsible for the conduct of the clinical study at a study site.  If a study is 
conducted by a team of individuals at a study site, the investigator is the responsible leader 
of the team and may be called the principal investigator.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 56
LY3298176MAD multiple ascending dose
MEN 2 multiple endocrine neoplasia syndrome type 2
MTC medullary thyroid carcinoma
open -label A study  in which there are no restrictions on knowledge of treatment allocation, therefore 
the investigator and the study participant are aware of the drug therapy received during the 
study.
PD pharmacodynamics
PFS pre-filled syringe
PHQ -9 Patient Health Questionnaire -9
PK pharmacokinetics
PK/PD pharmacokinetic/pharmacodynamic
PG plasma glucose
QW once-weekly
RNA ribonucleic acid
SAD single ascending dose
SAE serious adverse event
SC subcutaneous
screen The act of determining if an individual meets the minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study .  
SHSF Self-Harm Supplementar y Form
SMPG self-monitoring of plasma glucose
S[LOCATION_003]Rs suspected unexpected serious adverse reactions
TBL total bilirubin
TE-ADA treatment -emergent antidrug antibody
TEAE treatment -emergent adverse event :  Any untoward medical occurrence that emerges during 
a defined treatment period, having been absent pretreatment, or worsens relative to the 
pretreatment state ,anddoes not necessarily have to have a causal relationship with this 
treatment 
tmax time of maximum observed drug concentration
T2DM type2 diabetes mellitus
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117089] upper limit of normal
VAS visual analog scale
WOCBP woman of childbearing potential
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 58
LY3298176Appendix 2. Clinical Laboratory  Tests
Safety Laboratory Tests
Hematology a Clinical Chemistry (fasting) a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Glucose
Leukocytes (WBC) Blood urea nitrogen
Total protein
Absolute counts of: Albumin
Neutrophils Total bilirubin
Lymphocy tes Alkaline phosphatase
Monocytes Aspartate aminotransferase
Eosinophils Alanine aminotransferase
Basophils Creatinine
Platelets Amylase
Lipase
Hemoglobin A1c a,b
Urinaly sisaUric acid
Phospho rous
Calcitonin c
Follicle -stimulating hormone c
Specific gravity Hepatitis B surface antigen c,d
pH Hepatitis C antibody , hepatitis C RNA c,d
Protein HIV c,d
Glucose Pregnancy test e
Ketones
Bilirubin Lipid Panel (Fasting) a,b
Urobilinogen Triglycerides
Blood Total Cholesterol
Nitrite LDL
Microscopic examination of sediment f HDL
Abbreviations:  HIV = human immunodeficiency virus; RBC = red blood cells; WBC = w hite blood cells.
aPerformed by [CONTACT_12117].  Results will be validated by [CONTACT_105429].
bPerformed at Screening, Day  -2, Day  29, and FU/ED.
cPerformed by [CONTACT_105430] y.
dTests may  be waived if they  have been performed within [ADDRESS_117090] only if dipstick result is abnormal (i .e., positive for blood, protein, or nitrites) .
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117091] igator is responsible for:
ensuring that the subject understands the nature of the study ,the potential risks and 
benefits of part icipating in the study , and that thei r parti cipat ion is vo luntary.
ensuring that informed consent is given by [CONTACT_6992] .  This includes obtaining the 
appropriate signatures and dates on the ICF prior to the performance of any protocol 
procedures and prior to the administration of IP.
answering any quest ions the subject may have throughout the study  and sharing in a 
timely  manner any  new inform ation that m ay be relevant to the subject’s willingness to 
continue his or her participat ion in the study .
provi ding a copy  of the ICF to the parti cipant and retaining a copy  on file .
Recruitment
Lilly or i ts desi gnee is responsible fo r the central recruit ment strategy  for subject s.  Individual 
investigators may have addit ional local requirements or processes.   Study  specific recruit ment 
materi al should be approved by [CONTACT_11007] .
Ethical Review
The invest igator must give assurance that the ethical review board ( ERB )was properly 
constituted and convened as required by [CONTACT_105431].
Docum entati on of  ERB approval  of the protocol and the ICF must be provided to Lilly  before the 
study  may begin at the investigative site(s).  Lilly or its representatives must approve the ICF 
before i t is used at the invest igative site(s).  All ICFs must be compliant with the ICH guideline 
on GCP.
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
ICF 
relevant curri cula vi tae
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 60
LY3298176Regulatory Considerations
This study  will be conducted in accordance wit hthe protocol and with :
1)consensus ethics principles derived fro m internat ional ethics guidelines, 
including the Declarat ion of Helsinki and Council for International 
Organizat ions of Medical Sciences (CIOMS) Internat ional Ethi cal Guidelines 
2)applicable ICH GCP Guidelines 
3)applica ble laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third party  organizat ion.
Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, t he protocol accurately describes the planned design and conduct of the 
study .  
After reading the protocol, theprincipal invest igator will sign the protocol signature [CONTACT_25327] a copy  of the signed page to a Lilly representative.
Final Report Signature
[CONTACT_47559], indicat ing 
agreem ent wi th the analyses, results, and conclusio ns of the report.
The sponsor’s responsible medical officer and statistician will sign/approve the fina l clinical 
study  report for this study , confirming that, to the best of his or her knowledge, the report 
accurately describes the conduct and results of the study .
Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its represe ntatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate.
provi detraining to i nstruct the invest igators and study  coordinators.  This training will 
give instruction on the protocol, the complet ion of the eCRFs, and study  procedures.
make periodic visit s to the study  site.
be available for consultation and stay  in contact [CONTACT_47556], 
telephone, and/or fax.
review and evaluate eCRF data and/or use standard computer edits to detect errors in data 
collect ion.
conduct a qualit y review of the database .
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117092] source documents at the study  site.  The study  may be audi ted by  [CONTACT_47557]/or 
regul atory agencies at any  time.  Invest igators will be given notice before an audit occurs.
The invest igator will keep records of all original source data.  This might include laboratory 
tests, m edical records, and clinical notes.  If requested, the invest igator will provide the sponsor, 
applicable regulatory  agencies, and applicable ERBs with direct access to the original source 
docum ents.
Data Collection Tools/Source Data
An electronic data capture sy stem  will be used in this study .  The site must define and retain all 
source records and must maintain a record of any data where source data are directly entered into 
the data capture system.
Data Protection
Data systems used for the study  will have control s and requi rements in accordance wit h local 
data protecti onlaw.  
The p urpose and use of subject personal informat ion collected will be provided in a written 
docum ent to the subject by [CONTACT_1034] .
Study and Site Closure
Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its designee , the invest igator, or the ERB 
of the study  sitejudges it necessary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
Discontinuation of the Study
The study  will be discontinued if Lilly or it s designee judges it necessary for medical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117093]’s history , severi ty of liver injury , 
underlying disease, and geography .  Laboratory  assays shoul d preferably  be perform ed locally  
for faste r turnaround. 
Recommended Evaluation Competing Causes of Abnormal Liver Tests
1st Line Testing
ALT, AST, ALP, TBL, direct bilirubin, GGT, CK Routine follow up 
Thorough history of symptoms, co -existing medical 
conditio ns, concomitant medications, dietary and 
nutritio nal supplements, excessive exercise or muscle 
injury , alcohol consumption, illicit substances.  Systemic infection/ sepsis; ischemic/ congestive 
hepatic injury; gallstone disease; alcoholic liver 
disease; muscle injury/ rhabdomyolysis; 
acetaminophen toxicity; DILI due to another drug, 
herbal or dietary  supplement.  
Serum CK Muscle injury/rhabdomyolysis a
Anti-HAV (IgM) Acute HAV infection
HBsAg
Anti-HBc IgG, IgMAcute hepatitis B; exacerbation of chronic hepatitis B
Anti-HCV 
HCV RNA (PCR) bAcute hepatitis C c; exacerbation of chronic hepatitis C
Anti-HEV (IgG, IgM), HEV RNA d Acute hepatitis E
ANA, ASMA, quantitative immunoglobulins 
(IgG, IgM, IgA)Autoimmune hepatitis e
Hepatobiliary imaging 
(ultrasonography, CT scan, MRI, MRCP) fBiliary  obstruction; pancreatitis; gallstones; 
portal -vein/ hepatic vein thrombosis; hepatic 
metastasis 
2nd Line Testing
PT-INR For subjects with elevated TBL or suspected liver 
failure 
Serological tests for EBV, CMV, HSV 
May need to obtain acute and convalescent serological 
testsHepatic injury caused by [CONTACT_46064], EBV, HSV
EBV -DNA, CMV -DNA, HSV -DNA by [CONTACT_954].  
Liver biopsy needed to confirm HSVHepatic injury caused by [CONTACT_46064], EBV, HSV
Additional Tests g
Bone specific ALP (ALP fractionation) Differentiate bone from liver origin 
LKM -1 antibody Autoimmune hepatitis
Urinary  ethy lglucuro nide h, 
serum phosphatidylethanol iAlcoholic liver disease
Serum acetaminophen level; 
acetaminophen protein adductsAcetaminophen toxicity
Review of blood pressure, pulse, electrocardiogram, 
echocardiogram, cardiology consultIschemic or congestive hepatic injury 

I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 63
LY3298176Urine toxicology screen Hepatotoxicity due to cocaine, opi[INVESTIGATOR_105408]-HDV Hepatitis D 
Blood or urine cultures Systemic infection, sepsis
Serum ceruloplasmin, serum copper Slit lamp eyes 
examination for Kayser -Fleischer rings, genetic testingWilson’s disease
Abbreviations:  ALP = alkaline phosphatase; ALT = alanine aminotransferase; ANA =antinuclear antibody; 
anti- =antibody; ASMA =anti-smooth muscle antibody; AST = aspartate aminotransferase; CK = creatinine 
kinase; CMV =cytomegalovirus; CT =computed tomography; DILI = drug -induced liver injury; EBV =Epstein 
Bar Virus; GGT = gamma -glutamyl transferase; HAV = hepatitis A virus; HBc =hepatitis B core; 
HBsAg =hepatitis B surface antigen; HCV =hepatitis C virus; HDV =hepatitis D virus; HEV =hepatitis E 
virus; HSV =herpes simplex virus; Ig =immunoglobulin; INR =international normalized ratio; LKM -1 = liver 
kidney microsomal type 1; MRCP =magnetic resonance cholangiopancreatography; MRI =magnetic resonance 
imagi ng; PCR =polymerase chain reaction; PT -INR =prothrombin time -internatio nal no rmalized ratio; 
RNA =ribonucleic acid; TBL =total bilirubin.
aSerum AST typi[INVESTIGATOR_897] (although not always) is higher than ALT
bIf anti -HCV positive, HCV RNA is required to conf irm HCV infection
cAcute hepatitis C may be anti -HCV negative but HCV RNA positive 
dIf anti -HEV IgM positive, consider confirmation with HEV RNA by [CONTACT_105432] a diagnosis of autoimmune hepatitis 
fIf cholestat ic injury, MRCP may be recommended
gBased on medical history and clinical judgment
hAlcohol consumption in past [ADDRESS_117094] 3 weeks
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 64
LY3298176Appendix 5. Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
Protocol I8F -MC -GPHU Sampling Summary
PurposeBlood Volume 
per Sample (mL)Number of Blood 
SamplesTotal Volum e 
(mL)
Screening tests a,b 25 1 25
Safety laboratory tests a,b 12.5 5 62.5
Hemoglobin A1c b 4 4 16
Tirzepatide pharmacokinetics c 3 19(+3) 66
Immunogenicity c 10 4(+3) 70
Acetaminophen pharmaco dynamics c 3 35(+3) 114
6-point plasma glucose c 2 6 ×3 occasions 36
Plasma glucose c 2 9 18
Pharmacogenetics c 10 1 10
Total 417.5
Total for clinical purposes 420
aAdditional samples may be drawn if needed for safety purposes. Safety laboratory  tests will be inclusive of lipid 
panels on days when they are performed (refer to Appendix 2 )
bPerformed on site or in a local laboratory . 
c    Performed at a central or referral laboratory approved b y the sponsor , including for storage
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 65
LY3298176Appendix 6. Pancreatic Monitoring
Abbreviations:  CT = computed tomography; MRI = magnetic resonance imaging; ULN = upper limit of normal.

I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page [ADDRESS_117095] igators will be 
responsible for fo llowing, through an appropriate healthcare option, these pancreat itis AEs unt il 
the events resolve or are explained.  Adverse events that meet the diagnostic criteria of acute 
pancreat itis will be captured as SAEs.  For all other pancreatic AEs (such as idiopathic or 
asymptomat ic pancreat ic enzyme abnormalit ies), the invest igator will be responsible for 
determining the seriousness of the event (AE or SAE) and the relatedness of the event to study  
drug.
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e 6 7 
L Y 3 2 9 8 1 7 6 A p p e n di x 7. Pr ot o c ol A m e n d m e nt I 8 F -M C -G P H U ( a) 
S u m m ar y  
T h e I m p a ct of Tir z e p ati d e o n G a stri c E m pt y i n g ( G E) i n 
O v er w ei g ht/ O b e s e N o n -di a b eti c S u bj e ct s a n d i n 
O v er w ei g ht/ O b e s e S u bj e ct s wit h T y p e 2 Di a b et e s 
M e llit u s
O v er vi e w 
Pr ot oc ol  I 8 F -M C -G P H U ‘T he I m pact of  Ti rze pat i de o n Gastric E m pt yi n g ( G E) i n 
O ver wei g ht/ O bese N o n -di a bet ic S u bjects a n d i n O ver wei g ht/ O bese S u bjects wi t h  T y pe 2 
Di a betes Mellit us ’ has bee n a me n de d.  T he ne w pr ot oc ol is i n dicate d b y A me n d me nt ( a) a n d will 
be use d t o c o n d uct t he st u d y  i n pl ace of a n y prece di n g versi o n of t he pr ot oc ol.  T his a me n d me nt 
is c o nsi dere d t o be n o n- s u bsta ntial si nce it  d oes n ot alter t he s u bject safet y a n d t he pri mar y  a n d 
sec o n dar y o bject i ves of t he st u d y .
T he o verall c ha n ges a n d rati o nale f or t he c ha n ges ma de t o t h is pr ot oc ol are as f o ll o ws: 
Li pi d pa nel c ollect i o n ti me has bee n r e m o ve d fr o mt h e sc he d ule of act i vit ies ( Secti o n  2) 
t o a v oi d i nf or mat i o n d u plicati o n wi t h  A p pe n di x 2 . 
F o ot n ote attri b ut i o ns f o r he m o gl o bi n A 1c a n d li pi d pa nel o f A p pe n di x 2 ha ve bee n 
c o rrecte d .
Bl o o d sa m pli n g v ol u me liste d i n  A p pe n di x [ADDRESS_117096] ual la b orat or y  sa m pli n g re q ui re me nt. 
Mi n or e di t ori al c ha n ges a n d f o r m atti n g c orrecti o ns were m a de b ut are n ot necessaril y 
d oc u m e nte d i n t he re visi o n bel o w. C CI 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e 6 8 
L Y 3 2 9 8 1 7 6 R e vi s e d Pr ot o c ol S e cti o n s 
N ote: All deleti o ns ha ve bee n i de nt ifie d b y stri ket hr o u g hs .
All a d di ti o ns ha ve bee n i de nt ifie d b y t he use of u n dersc ore .
2. S c h e d ul e of A cti viti e s 
St u d y Sc he d ule Pr ot oc ol I 8 F -M C -G P H U Scree ni n g a n d B aseli ne 
Scree ni n g B aseli ne 
C o m me nts 
Pr oce d ure D- 2 8 t o - 4  D- 3  D- 2  D- 1 
… …  …  …  …  … 
Cli nical La b orat or y Tests X X Se e A p pe n di x [ADDRESS_117097] 
tir ze pati de d osi n g o n D 1. Perf or me d b y a l ocal la b o rat or y. 
… …  …  …  …  … .
Li pi d Pa nel X
St u d y Sc he d ule Pr ot oc ol I 8 F -M C -G P H U Tre at me nt a n d F oll o w -u p 
Tre at me nt a n d F oll o w U p C o m m e nts 
Pr oce d ure D 1  D 2  D 3  D 4  D 8 
± 1 D 1 5 
± 1 D 2 2 
± 1 D 2 9 
± 1 D 3 5 D 3 6  D 3 7 D 3 8 D 4 3 
± 2 F U/ 
E D a
… …  …  …  …  …  …  …  … …  …  …  …  …  …  … 
Cli nical 
La b orat or y 
Tests P P X  X Refer t o scree ni n g a n d 
baseli ne c o m me nts 
… …  …  …  …  …  …  …  …  …  …  …  …  …  …  … C CI C CI 
I 8 F -M C -G P H U Cli ni c al P h ar m a c ol o g y Pr ot o c ol ( a) P a g e [ADDRESS_117098] ci rc u mfere nce, a p petite 
V A S sc ores 
C CI C CI 
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 70
LY3298176Appendix 2 Clinical Laboratory Tests
Safety Laboratory Tests
Hematology a Clinical Chemistry (fasting) a
Hematocrit Sodium
Hemoglobin Potassium
Erythrocy te count (RBC) Bicarbonate
Mean cell volume Chloride
Mean cell hemoglobin Calcium
Mean cell hemoglobin concentration Glucose
Leukocytes (WBC) Blood urea nitrogen
Total protein
Absolute counts of: Albumin
Neutrophils Total bilirubin
Lymphocy tes Alkaline phosphatase
Monocytes Aspartate aminotransferase
Eosinophils Alanine aminotransferase
Basophils Creatinine
Platelets Amylase
Lipase
Hemoglobin A1c a,b
Urinaly sisaUric acid
Phospho rous
Calcitonin c
Follicle -stimulating hormone c
Specific gravity Hepatitis B surface antigen c,d
pH Hepatitis C antibody, hepatitis C RNA c,d
Protein HIV c,d
Glucose Pregnancy test e
Ketones
Bilirubin Lipid Panel (Fasting) a,cb
Urobilinogen Triglycerides
Blood Total Cholesterol
Nitrite LDL
Microscopic examination of sediment f HDL
Abbreviations:  HIV = human immunodeficiency virus; RBC = red blood cells; WBC = w hite blood cells.
aPerformed by [CONTACT_12117].  Results will be validated by [CONTACT_105429].
bPerformed at Screening, Day  -2, Day  29, and FU/ED.
cPerformed by [CONTACT_105430] y.
dTests may  be waived if they  have been pe rformed within [ADDRESS_117099] only  if dipstick result is abnormal (i.e., positive for blood, protein, or nitrites).
Appendix 5 Blood Sampling Summary
This table summarizes the approximate number of venipunctures and blood volumes for all 
blood sam pling (screening, safet y laboratori es,and bioanaly tical assays) during the study .  
I8F-MC-GPHU Clinical Pharmacology Protocol (a) Page 71
LY3298176Protocol I8F -MC -GPHU Sampling Summary
PurposeBlood Volume 
per Sample (mL)Number of Blood 
SamplesTotal Volume 
(mL)
Screening tests a,b 2125 1 2125
Safety laboratory tests a,b 1712.5 5 8562.5
Hemoglobin A1c b 4 4 16
Calcitonin b 2 1 2
Tirzepatide pharmacokinetics c 3 19 (+3) 66
Immunogenicity c 10 74(+3) [ZIP_CODE]
Acetaminophen pharmacodynamics c 23 35 (+3) [ZIP_CODE]
6-point plasma glucose c 2 6 × 3 occasions 36
Plasma glucose c 2 9 18
Pharmacogenetics c 10 1 10
Total 424417.5
Total for clinical purposes 423.5 420
aAdditional samples may be drawn if needed for safety purposes. Trigly cerides and total cholesterol will be 
excluded on study days where a lipid panel pharmacodynamics sample is collected. Safety laboratory tests will 
be inclusive of lipid panels on days when they  are performed (refer to Appendix 2)
bPerformed on site or in a local laboratory . 
c    Performed at a central or referral laboratory approved by [CONTACT_456] , including for storage
L e o  D o c u m e n t  I D  =  1 8 c f 7 e f 1 - 8 a 8 7 - 4 d 0 a - 8 1 6 0 - 6 1 8 6 d d 2 0 6 2 c 8 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 2 - J u l - 2 0 2 0  1 2 : 0 4 : 5 1  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d 
A p p r o v e r :  
A p p r o v a l  D a t e  &  T i m e :  2 3 - J u l - 2 0 2 0  0 0 : 2 4 : 0 6  G M T 
S i g n a t u r e  m e a n i n g :  A p p r o v e d P P D 
P P D 